WO2013040337A1 - Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer - Google Patents
Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer Download PDFInfo
- Publication number
- WO2013040337A1 WO2013040337A1 PCT/US2012/055387 US2012055387W WO2013040337A1 WO 2013040337 A1 WO2013040337 A1 WO 2013040337A1 US 2012055387 W US2012055387 W US 2012055387W WO 2013040337 A1 WO2013040337 A1 WO 2013040337A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- compound
- nhc
- amino
- hydrogen
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 94
- 206010028980 Neoplasm Diseases 0.000 title claims description 82
- 201000011510 cancer Diseases 0.000 title claims description 23
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 227
- 238000000034 method Methods 0.000 claims abstract description 108
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 41
- 206010014733 Endometrial cancer Diseases 0.000 claims abstract description 37
- 206010014759 Endometrial neoplasm Diseases 0.000 claims abstract description 37
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 35
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229960003881 letrozole Drugs 0.000 claims abstract description 26
- 201000003914 endometrial carcinoma Diseases 0.000 claims abstract description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 160
- 239000001257 hydrogen Substances 0.000 claims description 159
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 97
- 125000000217 alkyl group Chemical group 0.000 claims description 91
- 230000004044 response Effects 0.000 claims description 73
- 239000000203 mixture Substances 0.000 claims description 66
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 60
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 54
- 125000003545 alkoxy group Chemical group 0.000 claims description 51
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 48
- 201000010099 disease Diseases 0.000 claims description 46
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 42
- 230000008901 benefit Effects 0.000 claims description 39
- 125000001072 heteroaryl group Chemical group 0.000 claims description 34
- 239000002775 capsule Substances 0.000 claims description 30
- 239000012453 solvate Substances 0.000 claims description 27
- 230000006872 improvement Effects 0.000 claims description 23
- 239000007963 capsule composition Substances 0.000 claims description 22
- 230000036961 partial effect Effects 0.000 claims description 22
- 230000001225 therapeutic effect Effects 0.000 claims description 19
- 230000009467 reduction Effects 0.000 claims description 18
- 239000003886 aromatase inhibitor Substances 0.000 claims description 17
- 239000007916 tablet composition Substances 0.000 claims description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 15
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 230000000306 recurrent effect Effects 0.000 claims description 14
- 206010027476 Metastases Diseases 0.000 claims description 12
- 229940122815 Aromatase inhibitor Drugs 0.000 claims description 11
- 230000009401 metastasis Effects 0.000 claims description 11
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 9
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 9
- 108091008039 hormone receptors Proteins 0.000 claims description 8
- 230000001575 pathological effect Effects 0.000 claims description 8
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 13
- QINPEPAQOBZPOF-UHFFFAOYSA-N 2-amino-n-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 QINPEPAQOBZPOF-UHFFFAOYSA-N 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 230000002195 synergetic effect Effects 0.000 claims 1
- -1 hydroxy, cyano, amino Chemical group 0.000 description 122
- 229940126062 Compound A Drugs 0.000 description 108
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 108
- 125000005843 halogen group Chemical group 0.000 description 62
- 239000002904 solvent Substances 0.000 description 51
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 43
- 238000006243 chemical reaction Methods 0.000 description 41
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 37
- 239000002253 acid Substances 0.000 description 36
- 239000003826 tablet Substances 0.000 description 36
- 125000003118 aryl group Chemical group 0.000 description 28
- 125000003342 alkenyl group Chemical group 0.000 description 27
- 239000000243 solution Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- 239000000543 intermediate Substances 0.000 description 20
- 125000003710 aryl alkyl group Chemical group 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 18
- 125000004122 cyclic group Chemical group 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 150000003254 radicals Chemical class 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 13
- 125000004438 haloalkoxy group Chemical group 0.000 description 13
- 239000000651 prodrug Substances 0.000 description 13
- 229940002612 prodrug Drugs 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 125000003302 alkenyloxy group Chemical group 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 12
- 125000004093 cyano group Chemical group *C#N 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 125000000547 substituted alkyl group Chemical group 0.000 description 12
- 239000003643 water by type Substances 0.000 description 12
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 11
- 125000004429 atom Chemical group 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 125000001309 chloro group Chemical group Cl* 0.000 description 11
- 125000004663 dialkyl amino group Chemical group 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 11
- 238000004007 reversed phase HPLC Methods 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
- 238000013461 design Methods 0.000 description 10
- 102000003998 progesterone receptors Human genes 0.000 description 10
- 108090000468 progesterone receptors Proteins 0.000 description 10
- 208000037821 progressive disease Diseases 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 125000001188 haloalkyl group Chemical group 0.000 description 9
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 8
- 239000004215 Carbon black (E152) Substances 0.000 description 8
- 150000001408 amides Chemical group 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000000481 breast Anatomy 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229940011871 estrogen Drugs 0.000 description 8
- 239000000262 estrogen Substances 0.000 description 8
- 229930195733 hydrocarbon Natural products 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 8
- 230000003285 pharmacodynamic effect Effects 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 206010061818 Disease progression Diseases 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 125000002252 acyl group Chemical group 0.000 description 7
- 125000003282 alkyl amino group Chemical group 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- 230000005750 disease progression Effects 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 125000006413 ring segment Chemical group 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010055113 Breast cancer metastatic Diseases 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 6
- 229940046844 aromatase inhibitors Drugs 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 239000007903 gelatin capsule Substances 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 5
- 125000004414 alkyl thio group Chemical group 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 150000001204 N-oxides Chemical class 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 238000001794 hormone therapy Methods 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 125000005017 substituted alkenyl group Chemical group 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 4
- 229960005080 warfarin Drugs 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 201000004384 Alopecia Diseases 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 3
- 206010059282 Metastases to central nervous system Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 238000011319 anticancer therapy Methods 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 239000000460 chlorine Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 239000002274 desiccant Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 3
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 3
- 239000011630 iodine Chemical group 0.000 description 3
- 229910052740 iodine Chemical group 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229940080313 sodium starch Drugs 0.000 description 3
- 238000011301 standard therapy Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 235000019759 Maize starch Nutrition 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 101150034459 Parpbp gene Proteins 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 206010041235 Snoring Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 208000007814 Unstable Angina Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- 239000012042 active reagent Substances 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 125000005741 alkyl alkenyl group Chemical group 0.000 description 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 238000010640 amide synthesis reaction Methods 0.000 description 2
- 125000002431 aminoalkoxy group Chemical group 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002081 enamines Chemical class 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 238000006053 organic reaction Methods 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 231100000279 safety data Toxicity 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 231100000161 signs of toxicity Toxicity 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 231100000402 unacceptable toxicity Toxicity 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- QEJQAPYSVNHDJF-UHFFFAOYSA-N $l^{1}-oxidanylethyne Chemical compound [O]C#C QEJQAPYSVNHDJF-UHFFFAOYSA-N 0.000 description 1
- ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
- 125000001724 1,2,3-oxadiazol-4-yl group Chemical group [H]C1=C(*)N=NO1 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- FUJSJWRORKKPAI-UHFFFAOYSA-N 2-(2,4-dichlorophenoxy)acetyl chloride Chemical compound ClC(=O)COC1=CC=C(Cl)C=C1Cl FUJSJWRORKKPAI-UHFFFAOYSA-N 0.000 description 1
- XARVANDLQOZMMJ-CHHVJCJISA-N 2-[(z)-[1-(2-amino-1,3-thiazol-4-yl)-2-oxo-2-(2-oxoethylamino)ethylidene]amino]oxy-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)O\N=C(/C(=O)NCC=O)C1=CSC(N)=N1 XARVANDLQOZMMJ-CHHVJCJISA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229940126638 Akt inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241001466460 Alveolata Species 0.000 description 1
- 229930091051 Arenine Natural products 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 241000408939 Atalopedes campestris Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- KMKBEESNZAPKMP-UHFFFAOYSA-N Biphenylindanone a Chemical compound CC=1C(C)=C2C(=O)C(C3CCCC3)CC2=CC=1OCC(C=1)=CC=CC=1C1=CC=C(C(O)=O)C=C1 KMKBEESNZAPKMP-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- QEMPHSCPKNOUCW-UHFFFAOYSA-N CCC(C)c(cc(cc1)OC)c1N Chemical compound CCC(C)c(cc(cc1)OC)c1N QEMPHSCPKNOUCW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 101500022299 Dofleinia armata Delta-actitoxin-Dar1a Proteins 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000005431 Endometrioid Carcinoma Diseases 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 208000002633 Febrile Neutropenia Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241001069765 Fridericia <angiosperm> Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 241000288140 Gruiformes Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 244000286779 Hansenula anomala Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 240000001812 Hyssopus officinalis Species 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004726 Luranyl Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 101100125896 Neonectria sp. (strain DH2) iliC gene Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- OJJVRJWONUKKMI-UHFFFAOYSA-N O=[Si]=O.CCCCCCCCCCCCCCCCCC(O)=O Chemical compound O=[Si]=O.CCCCCCCCCCCCCCCCCC(O)=O OJJVRJWONUKKMI-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 241001237728 Precis Species 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 101150004182 RER2 gene Proteins 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 241000490025 Schefflera digitata Species 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 201000001256 adenosarcoma Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- QXAITBQSYVNQDR-UHFFFAOYSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1N=CN(C)C=NC1=CC=C(C)C=C1C QXAITBQSYVNQDR-UHFFFAOYSA-N 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 238000007080 aromatic substitution reaction Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- AXLOCHLTNQDFFS-BESJYZOMSA-N azastene Chemical compound C([C@H]1[C@@H]2CC[C@@]([C@]2(CC[C@@H]1[C@@]1(C)C2)C)(O)C)C=C1C(C)(C)C1=C2C=NO1 AXLOCHLTNQDFFS-BESJYZOMSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- 125000004966 cyanoalkyl group Chemical group 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- WMVRXDZNYVJBAH-UHFFFAOYSA-N dioxoiron Chemical compound O=[Fe]=O WMVRXDZNYVJBAH-UHFFFAOYSA-N 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 208000028730 endometrioid adenocarcinoma Diseases 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229940087476 femara Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000006005 fluoroethoxy group Chemical group 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 208000027706 hormone receptor-positive breast cancer Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229940080456 letrozole 2.5 mg Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 235000015250 liver sausages Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- AQIAIZBHFAKICS-UHFFFAOYSA-N methylaminomethyl Chemical compound [CH2]NC AQIAIZBHFAKICS-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
- 229940099990 ogen Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 1
- 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000011375 palliative radiation therapy Methods 0.000 description 1
- 201000005163 papillary serous adenocarcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- WFIZEGIEIOHZCP-UHFFFAOYSA-M potassium formate Chemical compound [K+].[O-]C=O WFIZEGIEIOHZCP-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003140 primary amides Chemical class 0.000 description 1
- 208000030266 primary brain neoplasm Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011268 retreatment Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- JOKPITBUODAHEN-UHFFFAOYSA-N sulfanylideneplatinum Chemical compound [Pt]=S JOKPITBUODAHEN-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940117013 triethanolamine oleate Drugs 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- Endometrial cancer (EC) and breast cancer affect thousands of patients in the United States and internationally every year. Endometrial cancer is currently the most common gynecologic malignancy in the United Sta es and the fourth most common cancer am ng women. The American Cancer Society estimates that there will he 42, 160 new cases cl: uterine cancer in 2009 and 7,7-80 related deaths. Ninety percent of cases occur in women older than 50 years, and the median age at diagnosis is 62 years. Endometrial cancer is more common among white- ' women than black women, yet mortality rates are higher in the latter. The overall annual ' mortality rate in the United S tates has increased more than 100 ' percent during the past two decades and is currently four deaths per 100,000 women per year.
- EC is a heterogeneous disease that has been classified into two subtype based on distinct elmicapathologicai and molecular characteristics.
- Type f is estrogen dependent and represents approximately 80% of sporadic eases. This subtype is well differentiated (Grade I or 2 endometrioid histology) and has a favorable prognosis.
- Phosphatase and fensiu homolog • on chromosome 10 (PTEN) loss (32-83%) and RAS mutations ( 10-30%) have been predominantl identified in Type 1 EC (Oda et at.
- Type ⁇ is poorly differentiated (Grade 3 endometrioid, clear cell, and papillary serous carcinoma) and not associated with increased circulating estrogens. This subtype has an aggressive clinical course and poor prognosis, p3 i frequently mutated in Type- II EC (Doll et ah 2008). There is evidence that the P1IC3CA pathway may be- activated in both type 1 and type II EC and by differing mechanisms (Saivesen 2009).
- Aromatas.ft# Two highly- selective nonsteroidal aromatase inhibitors anasirozole (Arimidex$) and ietrozole (Femara®) and the steroidal aromatase inhibitor exciuestane (Aromas.ft#) are approved for use in both early- and advanced-stage breast ' cancers in postmenopausal women.
- Aromatase inhibitors such as lejrozole are effective in treatment o hormone receptor-positive breast cancer; ho wever, many minors become resistant t aromatase inhibitors.
- methods for treating endometrial carcinoma comprising administering to a patient in. need thereof a therapeutically effective amount of a Compound of Formula I or of Formula- II or a single isomer thereof or optionally as a pharaYaeetiticaliy acceptable salt, tautomer, hydrate, or solvate thereof:
- ⁇ N an .the remaining are -C(R f ⁇ :;:; ; and where each R ! is independently hydrogen, alkyl, haSoalkyl, iiitro, alkoxy, haloalkoxy, halo, hydroxy, cyano, amino, alkyl amino. Of djaikyiamino;
- R* s is hydrogen or alkyl
- R ii! , R 55 , and R S i are independently hydrogen, a!kyi, alkenyl halo, haioa!kyl, ha!oaikenyl hydroxy, alkoxy, alkenyioxy, haloalkoxy, niiro, amino, alkyiarnmo, dialkylamino, -N(R 55 ⁇ C(0)-CrC 6 -alkyleac- (R )R 53 ⁇ 4 ⁇ alkylc ' srfomyl, alkenykarhonyl, earboxy, aikoxyearbonyi, cyano, a!kyifhio,
- R >>B are independentit hydrogen, atkyl, or alkenyl and ⁇ is hydrogen, alkyl alkenyl hydroxy, or alkoxy; or R s" and R ! together with the carbons to which they are attached form a 5- or S-membered. heteroaryl or 5- or 6-membered beteroeyctoalkyJ;
- B is phenyl substituted ws.ih : R ',il and optionally iurther substituted with one, two, or three R ! ; or
- B is heteroaryl optionally substituted with one, two, or three R 3 ;
- R' 3 is cyano; hydroxyamino; carboxy; aikoxyearbonyi; alkylaraino; dialkylamino;
- alkylearhonyk haloalkoxy alkylsulfonyl; aminoaikyloxy; alfcylaminoa!kyloxy;
- R 7 is hydrogen, alkyl, or alkenyl and R' a and R'* are independently hydrogen, alkyl, alkenyl, hydroxyalkyl hatoaikyl, alkoxy, alkoxyalkyl,.
- R 5 is hydrogen, hydroxy, alkoxy. alkyl, alkenyl, haloalkyl,. or haloalkoxy and ⁇ is hydrogen, alkyl, alkenyl, hydroxyalkyl, cyanoalkyl,
- heteroeycloalkylalkyl and heieroaryiaikyl ⁇ are from aikyl, alkenyi, alkoxy, halo, haioalkyl, haloalkoxy, hydroxy, hydroxyalkyl, ox.6, amino, aikyiamino, dlalkylamiao, alkyJcarboayl, aminoalkyl, alkylaminoalkyl, diaikyiaminoalkyi, alkoxycarbpnyl, and -Cf )H;
- heterocyeloaikyl rings in R 3 ⁇ 4 are independently optionally substituted with 1, 2, or 3 groups independently selected from alky].
- aryf optionalally subsiiteied with one or two halo
- ary!alkyi heidfoaryl.
- R ! is hydrogen, hydroxy, alkoxy, alkyL alkenyi, haioalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, or hydroxyalkyl and R'" and * are ' independently hydrogen, a!kyl, alkenyi, haioalkyl, aramoaikyt, alkylaminoalkyl, dialkylaminoalkyl. or hydroxyatkyk
- R l is hydrogen, alkyl, aSkenyi, hydroxy, or alkoxy and R u and R' ! 3 ⁇ 4> are independently hydrogen, alky I, alkenyi, amitioaikyl, alkylaminpalkyl, or dialkylaminoalkyl;
- u is heterocyeloaikyl optionally substituted with 1 , 2, or 3 groups selected from alkyl, oxo, amino, alkylanSino, and he.teroeycloalkylal.kyl;
- R is hydrogen, alkyl, or alkenyi and R ! 3 ⁇ 4 is aminoalkyl, .alkylaminoalkyl, diaikylammoalkyk aryl, or arylalkyl;
- R ! s , and R i4b are independently hydrogen, alkyL or alkenyi;
- R lk ⁇ R' ft , and R !ib are independently hydrogen, alkyl, or alkenyi;
- R l " is hydrogen, aikyl, or alkenyi
- R ! i i is alkyl or aikenyi
- heteroaryl optionally substituted with one -or two aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl: independently hydrogen, aikyl, of alkenyi;
- R t Sn is hydrogen, a!kyt, alkenyi, or alkoxy and R 5 and R 1 b are ' iadepeiideijtly -hydrogen, -alkyl, or alkenyi;
- R ' 3 is amino, alfcylamino. dialkylamino, or heterocycloaikyl
- R- 26 is hydrogen, -aikyl, or alkenyi
- R 3 ⁇ 4la is cycteiky!. or heterocyei alkyl
- R 21 S(0)rCrCV ⁇ Ikykne-N ⁇ R 2,fe ⁇ R 2
- R 2S is hydrogen, aikyl or alkenyi
- 2 fa and R 2i3 ⁇ 4 are independently hydrogen, alkyl, or alkenyi
- R 2 ⁇ R 2Sa and R 23b are independently .hydro-gen, alkyl, or alkenyi; or
- aikoxyaikyl or aryi optionally substituted with one or two halo: or alkyl; and where each of the -aikylene in R 3 ⁇ 4 is - independently Optionally further substituted with 1, 2, 3,
- each R " ' (when R 1 is present) is independently alkyl; alkenyi; alkynyl; halo; hydroxy; oxo; alkoxy; eyano hydro syaniino; earhoxy; alfcoxye rbonyl; amino; alkylaraino;
- dialkylamino aikylearbonyl; hatoaikoxy; alkylsultbnyl; aminoa!kyloxy;
- alkyla inoatkyloxy dialfcyiammoalkyloxy
- R 7 is hydrogen, alkyl, or aikenvi and R :a and R ;b are Independently hydrogen, alkyl, alkenyi, hydroxyalkyl, haioalkyl, alkoxy, aikoxyaikyl-, atninoaikyL aiky!araiooa!kyl dialkyla moaikyi, cycloalfcyi, eyeioalkylaikyl, heteroeycloalkyi, heteroeycloaikylaikyl heteroary ' L .heter arylalkyl, aryi, arylalkyl, or aryklkyioxy and where the aryi, cyeloalkyi, heieroeyeioalkyl and lieteroaryl rings in R' ' * and R' h (either alone or as part of ary!
- R sa is hydrogen, aikyl, alkenyi, hydroxyalkyl, eyanoalkyi, aikoxyaikyl, alkylthioalkyl, heterocycloaikyl heierocycioidkylalkyl, cyeloalkyi, cyeloaiky!, heteroaryl, and heterocyeloalkyl rings in R* 3 (cither alone or as part of arylalkyi, cyeloal ylaikyS, hcteroeye alkylalkyl and heiemaryiaSkyl) are
- alkyl independently optionally substituted with I, 2, or 3 groups independently selected from alkyl. alkenyl, alkoxy. halo, lialoalkyl, haioalkoxy,- hydroxy, hydroxyalkyi, oxo, amino, alkySarnino, dtalkylamino, aikylearbonyl, aminoalkyl, alkylarninoalkyl, iiialkylaminoaikyl, alkoxycarbony!, and -C(0)H;
- c) ⁇ NR*C(Q)R 3 ⁇ 4 where is hydrogea, hydroxy, alkoxy, alkyk alkenyl, lialoalkyl, or haioalkoxy and s'a is hydrogen, C; ⁇ CVa!kyl, alkenyl, hydroxyalkyi, alkoxyalkyk eycioa!kyl, cycioaikylaikyl, heterocyeloalkyl, heteroeycloalkyiaikyl, heteroaryl heteroaryia!kyi aryl or arylalkyi; where the aryl cycioalkyi, heteroaryl, and heterocyeloalkyi rings in R a (either alone or as part of arylalkyi, cyeioaikylalkyl heteroeycloalkyiaikyl and heteroarykikyl ⁇ are independently optionally substituted with 1 , 2, or 3 groups independently selected froni
- R ! ] :i is hydrogen, aikyl, alkenyl, hydroxy, or alkoxy and R ! i and R ui> are independently hydrogen, aikyl alkenyl, aminoalkyl,
- R ;2 is heteroeycioaikyl optionally substituted with 1, 2, or 3 groups selected ftom alkyl, oxo, amino, alkylanuno, and heteroeyeloalkyialkyl;
- R H , R m , and R 5 b are independently hydrogen, alkyl, or alkenyl;
- R 13 , R iS and R J 5h are independently hydrogen, alkyl, or alkenyl;
- R tS is hydrogen, alkyl or alkenyl and R ; ⁇ 3 ⁇ 4i is alky! or alkenyl; dialkylaminoalkyl;
- R i?> and R m ⁇ are independently hydrogen, alkyl, or alkenyi;
- 1 5 8 is amino, aikylammi dialkvlaramo, or heiereeyeloalkyl
- R" 3 ⁇ 4> is eycioalkyl or fieteroeycloalky!
- R " i!i and R m are independently hydrogen, alkyk or alkenyi;
- R 22 , R 22a and R" 3 ⁇ 4 are independently hydrogen, alkyk or alkeayl;
- R 3 R 25a and ft 2 * are independently hydrogen, alkyl, or alkenyi; or
- R 24a is alkoxyalkyl or aryl optionally substituted with one or two halo or alkyl;
- each of the alkyl ene in R' is independently optionally i ' urther substituted with i . 2, 3,
- R 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and diaikylamino; and provided that when R > and R ⁇ are hydrogen, R 3i is hydrogen or methyl, R ' " ' is hydrogen or methoxy, and R " " is hydrogen or tnethoxy, then B is not 2,3-dihydn -i ,4-be:iiz;odios.fnyi, tliien-2- ⁇ , o thien-2 ⁇ yi substituted, with one R' where R is halo
- K is hydrogen, optionally substituted alkyk optionally substituted eycioalkyl, optionally substituted cydoaikylalkyk optionally substituted ary optionally substituted arylalkyl, optionally substituted heteroeycloalkyS, optionally substituted hetemaryklkyl;
- * is hydrogen or alkyl where the alky! is optionally substituted ' with. 1 , , 3, 4, or 5 R ' groups;
- X is -NR 3 -;
- R* optionally substituted alkyl
- R" is phenyl, acyl, or heteroaryl wherein the phenyl and hetero&ryl are optionally substituted with 1 , 2, 3, 4, or 5 R 'J groups;
- each R s when present, is independently hydroxy, halo, aikoxy, haloaikoxy, amino, alkyiaroino, dialky!ammoalkyl, or alkoxyalky!amino;
- each Rvwheti present is independently halo, alkyl, haloalkyl, aikoxy, ha!oalkox , c ariOj amino, alkyiamino, dia!kylamtno, altoxvalkyl, carhoxya!kyl, alkoxycarbonyl, amin alkyL eycloaikyi, aryi, arylalkyi, aryloXy * heteraeyclOalkyl, or heteroaryi and where the eycloaikyi, aryi hetepoeyeloalkyl, and lieteroaryh each either alone or as part : bf another group within R ⁇ are independently optionally substituted with 1, 2, 3, or 4 groups selected .from. halo, alkyl, ba alkyi hydroxy, aikoxy, haioalkxy, amino, alkylanii.no, -and
- the compound of Formula I is a compound of .Formula la
- R ' is hydrogen
- A is methyl
- R '' ⁇ is hydrogen
- R i" ⁇ is hydrogen or ' aikoxy; and which they are attached form a ⁇ -membered heteroaryl; arid
- R" is hal or meihy!.
- R 3 * is -N(R ? )C ⁇ 0)-CrC ⁇ ailcylene-N(R. 3 ⁇ 4 )(R 7 ) where R T is hydrogen and R 3 ⁇ 4 and R ' ⁇ are independently hydrogen, alky!, aniino lkyk. aikytemmoalkyl, or
- the Compound of Formula 11 is a compound of formula II A.
- R ! is alkyi,. cyeloalkyl, eycloalky!alkyl, aryl, arylalkyl, heterocycloalkyl,
- R" is hydrogen or a!kyl
- R is alkyl
- R ' is hydrogen
- R" is enyl, acyl or heteroaryl wherein the phenyl and heteroaryl arc is optionally substituted with 1 , 2, 3. 4, or 5 R groups;
- each R when present, is independently halo, alfcyl, !ialoaikyh alkoxy, haioaikoxy. cyano, -amino, aikylanilao, dialkylaraino, aikoxyaikyl, earboxyalkyl, alkoxycarborryi, aminoalkyk c cioalkyl .aryl, .arylalkyl,. arylpx-y, heterocycloalkyk or heteroaryl and where the
- 1.0 group un K " ' are independently optionally substituted with 1 , 2, 3, or 4 groups selected from halo, alkyl, haloalkyl, hydroxy, alkoxy, ha!oalkoxy, amino, alkylamsno, and diaSk lamino,
- Compound B is known by its name 2-an:iim)-8-ethyl-4-inediy!-6- ⁇ 1 /-pyi3 ⁇ 43 ⁇ 4K>l-3- yl)pyrido
- the cancer is Type I or Type II .endometrial carcinoma (
- the cancer is advanced or recurrent endometrial carcinoma
- ie compound or " Formula I or Formula 11 is administered as a tablet or capsule pharmaceutical composition.
- the compound of Formula I or Formula II is administered as a tablet pharmaceutical composition.
- the compound of Formula 1 or !.l is fidniinistered in an effective amount, wherein the effecti ve amount produces at least one therapeutic effect selected from the group . consisting of reduction in sixe of a tumor, reduction in metastasis, complete.. remission, partial remission, stable disease, increase in overall response rate, or a pathologic complete response,
- methods are provided herein for treating breast cancer comprising administering to a patient in need thereof a therapeutically effecti ve amount of letr Koie in combination with a Compound ' of Fonnula 1, la, or Compound A as described herein;: or letrosiqie in combinatio with Compound it, 11A, or Compoun B as described herein.
- the compound of ⁇ Formula I or Formula 11 is administered orally as a tablet or capsule pharmaceutical composition
- the compound of Fonnula 1 or Fonnula II is administered as a t bl t pharmaceutical composition
- the -effective amount produces at least one therapeutic effect selected from the group consisting of redaction in size of a tumor, reduction in metastasis, complete remission, partial remission, stable disease, increase in overall response rate, or a pathologic complete response,
- Figure 1 shows a plot of individual and mean SD (Bold, horizontal lines with error bars) for Compound ⁇ AUCiQ-24), ss after doses of 200 and 400 mg tablets in Arm 1 compared to historical data (TEDS 1433 & A D I 1439) ibr Compound A.
- Figure 2 shows a plot individual and mean/SD (Bold, horizontal lines with error bars) for Compound B AUC ⁇ 0- 12), ss alter doses of 30 and ' 50 mg capsules BIO in Ann 2 compared to historical data (TED U 440) for Compound B (above).
- Figure 3 depicts preliminary results from a Phase I results from a breast cancer clinical trial.
- Figure 4 depicts preliminary results from a Phase I results from, a breast cancer clinical trial.
- Figure 5 depicts preliminary results from a Phase I results from a breast cancer clinical trial.
- a substituent "R.” may reside on any atom of the ring system, assuming replacement of a depicted, implied, or expressly deiined hydrogen from one of the ring atoms * , so long as a stable structure is. formed..
- a substituent R" - may reside on any atom of the fused ring system, assuming replacement of a depicted hydrogen (for example the - ⁇ - in the formula above), implied hydrogen (for example as is the formula above, where the .hydrogens are not shown but understood to be present), or expressly defined hydrogen (for example where in the formula above, U " equals -CH-) from one of the ring atoms, s long as a stable ⁇ -structure is formed.
- the group may reside on either the 5-memhered or the 6-merabered ring of the fused ring system.
- the two "RV may reside on any two atoms of the ring system, again assuming each replaces a depicted, implied. Or expressly defined hydrogen on the ring,
- -Ac r means a -C(0)R radical where R is optionally substituted alkyl, optionally substituted aikenyl, cycioalkyL cyeloalkySaikyl, ary!, atalkyi, heteroaryl, heferoan kyl, hereroc cloalkyl, or h terocyeioaikylalkyl, as defined herein, e.g., acetyl,
- Aeylaramo means a -NRR " radical where R is hydrogen, hydroxy, alkyl, or aikoxy and R ' is aeyl, as defined herein.
- Acyloxy means an -OR radical where R is aeyl, as defined herein, e.g.
- administering * ' a compound in reference to a compound of the invention means mfrodue ing the compound or a prodrug of the compound into the system of the. animal in need of treatment.
- administration * ' and its variants are each understood to include concurrent and sequential introduction of the compound or prodrug thereof and other agents.
- AlkenyP means a means a linear monovalent hydrocarbon radical of one to si carbon atoms or -a branched monovalent hydrocarbon radical of three to 6 carbon atoms which radical contains at least one double bond, e.g., ethenyl, propeny!, i -but-3-enyl, and l -pc t-3-enyI, and the like.
- Aikoxy ** means an -OR group where R is alkyl group as defined herein.
- Examples include methoxy, ethoxy, propoxy, isop opoxy, and the like.
- AlkoxyalkyP means an alkyl group, as defined .herein, substituted with at least one, preferably one, two, or three, aikoxy groups- as defined herein. Representative examples include metho.xymethyl and the tike.
- Alkoxyalk lammo means an - RR' group where R is hydrogen, alkyl, or alkoxyalkyl and R' is aikoxyalky), as defined herein. specifically one or two, alkoxyalkylamino groupis), as defined herein.
- Alkoxyq-ar oayF means a -C(0) group where R is alfcoxy, as defined herein.
- Alkyl means a linear saturated monovalent hydrocarbon radieal of one to six ' carbon atoms or a branched saturated monovalent hydrocarbon radical of three to 6 carbon atoms, e.g., methyl ethyl, propyl, 2-propyi, butyl (including all isomeric forms), or peniyS (including all isomeric forms), and the like.
- I0048 ⁇ i Aikytamino means an -HH group where 11 is aikyi, as defined herein.
- 'Alfcyiaminna!kyn means an alky! group substituted with one or two aiky!amino groups, as defined herein.
- ⁇ OOSOj 'V ky!a inoaikyloxy means an O gr up where R is alkyiaminoaikyk as defined herein.
- Si Aikyiearbonyr means a -CfO)R group where R is aikyi. as defined herein.
- Alkynyt means a linear mono valent hydrocarbon radical of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to 6 carbon, atoms which radical contains at least one triple bond, e.g., eihynyl, prepynyl, buty yl, pewiyN-2-yl and the like.
- Alkyr means an alky! group substituted with at least one, specifically one, two Or three,, amino groups,
- 'Aminoaiky!oxy means an -OR group whereR is aminoaikyt,. as defined herein, 100663 "AryP means a monovalent six- to tburteen- embered,. mono- or bi-carbocyclic ring, wherein the monocyclic, ring is aromatic and at least one of the rings in the bicyclic ring is aromatic. Unless stated otherwise, the valency of the group may be located on any atom of any ring within the radical, valency tides permitting. Representative examples include phenyl, riaphthy.l, and indany!, and die like,
- Arylalky means an alkyl radical, as defined herein, substituted with one or two aryl groups, a defined herein, e.g., ben3 ⁇ 4yl and phenethyl, and the like.
- Aryloxy means an -OR group where R is and, as. defined herein.
- Carboxyalkyl means an alky! group, as .defined herein, substituted with at least one, specifically one or two, ⁇ C(0)OH ,grbtjp(s).
- eycltialkyl includes, bu is not limited to, cyclopropyl, cyelobutyi, cycloperityl, cyclohexyl, cyclohexyl, or eyclohex ⁇ 3 ⁇ enyl, and die like.
- Cycloaikylalkyl means an aikyl group substituted with at least one, specifically one or two, eyeloalky! group(s) as defined herein.
- Dialkylaraino means a -NRR' radical where R and * are aikyl as defined herein, or an -oxide derivative, or a protected derivative thereof, e.g., dunethylami V, dJethylamiao, A V-methylpropylamino or iV-raetJiylethylamino, and the like.
- Dia!kylaminoa!liyl means an aikyl group substituted with One or two
- ⁇ Dialkylaminoalkyloxy means an -OR group where R is dialkySamirioalky as defined herein. Representative examples include 2-(A' N-diethy1amrao)-eihyloxy, and the like.
- ⁇ 0065 "Fused-polycyelie ⁇ or "fused ring system” means a poiycyclic ring system that contains bridged or fused rings; that is, where too rings have more than one shared atom in their ring structures, in this. application, iused-polycyclies and fused ring systems are not necessarily ail aromatic ring systems.
- fiised-poiycycltcs share a vicinal set of atoms, for example naphthalene or 1,2,3,4-tetrahydtO-naphtlia!ene.
- a spiro ring sys ' tein is not a fused-polyeyciie by this definition, but fused; poiycyclic ring systems of the invention may themselves have spiro rings attached thereto via a single ring atom of the fused-polyeyciie. in some examples, as appreciated by on of ordinary skill in the art, two adjacent groups on an aromatic system may be fused together to forxn-.a ring- structure.
- the fused ring structure may contain heieroatoms and may be optionally substituted with one or more groups. It should additionally be noted ' that- 'saturated carbons of such fused groups (i.e. saturated ring. ' structures) can contain two substitution groups.
- Halogen or halo refers to fluorine, chlorine, bromine or iodine.
- Haloalkoxy means an -OR' group where R ! is haloaikyl as defined herein, e.g.. trifluoromet oxy or 2,2,2-tri ' fluoroethoxy, find the like,
- Haloalk ⁇ mean an aikyl grou substituted with one or snore halogens
- halo atoms e.g., trifluororaethyL 2-chloroethyl, and 2,2-difiuoroetiiyl, and the like,
- 0069j ''ReteroaryF' means a pionoeyclic.
- One or two ring carbon atoms of any nonaromatic . rings comprising a bieyclic -or tricyclic radical may be replaced by a -C(0)-, -C(S , or ⁇ C( ⁇ NH)- group.
- R x is hydrogen, alkyl, hydroxy, alfcoxy, acyl, or alkylsu!foiiyi, Fused hicyclic radical inerutles bridged ring systems.
- the valency may be located on any atom of any ring of the heteroaryi group, valency rules penm ' tting. When the point of valency is located on the nitrogen, R' s Is absent. More specifically, the term heteroaryl includes, but is not limited to, 1,2,4-triazolyi. 1.3,5-triazolyi.
- phthalimidyl pyridinyl, pyrrolyl, imidazoiyL thienyl, ftiranyi, kdoly " 2,3-dihydro-1 H-iodoIyl (including, for example, 2,3 ⁇ dthydro- l/:/-mcloi ⁇ 2-yl or and the like), ispirtdolylJndolinyl, isoindolinyi.
- benzothienyl and the derivatives ⁇ thereof, or N-oxide or a protected derivative thereof.
- 'ileteroary iaik ' means an alkyl group, as defined herein, substituted with at least one, specifically one or two heteroaiyi group(s), as defined herein,
- HeierQcycloalkyl means a saturated or partially unsaturated (but net aromatic) monovalent monocyclic group of to 8 ring, atoms or a saturated or partially unsaturated (but not aromatic) monovalent fused bieyclic group- of 5 to 12 ring atoms krwiheh one or more, specifically one, two, three, or- four ring heteroatoms independently selected from 0, S(0 ⁇ « (n is 0, 1, or 2), N, (R y ) (where R y is hydrogen, alkyl, hydroxy, alkoxy, acyl, or alkyteulfonyi ⁇ , the remaining ring atoms being carbon. One- or two.
- rin carbon atoms may- be replaced b -G(QH ⁇ €(SK 0r ⁇ C( ⁇ NH)- group.
- Fused bieyclic radical includes bridged ring systems. Unless otherwise stated, the valency of the group ma be loca ted on any ato m of any ring within the radical, valency rales permitting. When .”the point of valenc is located on a nitrogen atom, R J: is absent More specifically the term he erocycloalkyl includes, but is not limited to.
- azetidkr l pyrrolidinyi 2-osopyrrolidinyl, 2,5-dthydro- iH-pyrrolyl, pipertditryl, 2-oxopiperidmyi, thiamorpholinyk auaraorphoiinyl, perhydroazepinyl, pyrazolidmyl, imidazolmyl, imidazolldiny ⁇ .
- an alky! radical as defined herein, substituted with one or two heterocycloalkyl groups, -as defined herein, e,g., morpholinyirneihyl, jY-pyxrolidinylethyl, . and ' 3- ⁇ N>azeudtny!propyl, and the like.
- Heierocycloalkylaikylo . xy means an -OR group where R is heterocycloaikytidkyi, as defined herein,
- saturated bridged ring syst m ** refers to a bieyciie or polycystic ring system that is not aromatic. Such a system may contain isolated or conjugated unsaturatwn, but not aromatic or heteroaroruatie rings in its core structure ⁇ but may have aromatic substitution thereon). For example, hexahydro-i3 ⁇ 4roji3.2-b]furan, ⁇
- Spirocyelyr or “spirocyelic ring” refers to a ring originatin from a particular annular carbon of another ring.
- a ring atom of a saturated bridged ring system (rings B and B), but not a bridgehead atom, can foe a shared, atom between the saturated bridged ring system and a spiroeyelyl (ring A) attached thereto.
- a spiroeyelyl can he carbocyclic.or heteroalieyelic.
- Optionally substituted aSkyP means an alkyi radical, as defined herein, optionally substituted with one or more group(s), specifically one, two, three, four, or five groups, .independently selected from, alkylcarboiiyk aikenyiearbonyl, eycloalkyIeart>onyl, alk lcarbonyioxy, alkcnykarbony xy, amino, alkylamiao, diaikylamino, -aminocarbonyl, aikytominocarhonyl. dialkylaminoearhonyl, eyano, cyanoalkylaminoearbonyl., alkoxy.
- alky!3 ⁇ 4ulfonyl-NR e ⁇ (where R c is hydrogen, alkyi, optionally substituted alkenyl hydroxy, aikoxy, alkenyloxy, or eyaaoalkyl)* alkylaminocarboayloxy, dialkylatninocarbonyloxy, alkykrainoalkyibxy, dia!ky!anunDalkyloxy, alkoxyearbony!, lkenyloxycarbonyl,
- alkoxycarbojjylamino alkylamiiiocarbonyiamirio, dia!kylaminoe-arbonylamuio,
- R a and R b are independently hydrogen, alkyi,. optionally stibstituted alkeivyl, hydroxy, alkoxy, alkenyloxy, or cyanoalkyi
- Optionally substituted alkenyf * means an alkyi -.radical, as defined herein, optionally substituted with one or more group(s), specifically one, two, three, four, or five groups, independently selected from alk tearbonyi , a-1 kenylearbonyl, eye loa Ikylcarbonyl, alkylearbonykTxy, : aikenyiearbonyloxy, ami * alkylamino, dialkyianiino, aminocarbonyl, alkylaminocarbonyi, dialkylaminoearhonyl, eyano, eyanoalkylaminoearbonyl, alkoxy, alkenyloxy, hydroxy,, hydrosyalkoxy, halo, earboxy,- alky!earbonylainino, alkylearbonyloxy, aik i-SfO);),!-, alfcenyl-S(0) ⁇ >:r
- R i and R fe are independently hydrogen, alkyi, optionally .substituted alkeoyl, hydroxy, alkoxy, alkenyloxy, or cyanoalkyi).
- Optionally substituted amino refers to the group -N(H)R or-N(R)R where each R is independently selected irom the grotspt optionally substituted alkyi.,.
- Optionally substituted alkoxy optionally substituted aryl, optionally substituted heteroeycloalkyl. substituted alkyS
- ⁇ S(0).2-optioria11y substituted ary-l optionally substituted ary-l
- substituted heteroaryi includes- dietlvylaraino, methyisulfonyianrmo, and furanyl-oxy-suUbnanirao.
- [ 0821 ' 'Optionally substitute ' aminoalkyr means an aikyl group, as defined herein, substituted with at least one, specifically one or two. optionally substituted amino group(s), as defined herein,
- Optionally substituted ary! ' ' means an and group, as defined herein, optionally substituted with one, two, or three subatituents independently selected from aeyl, aeylamino, aeyloxy, optionally substituted alkyl, optionally substituted alkenyl, alkoxy, a!kcny!oxy, halo, hydroxy, afkoxycarbonyl, alkenyloxycarbonyl, amino, alkyiaraino, diaikylamino, nitro, aminoearboayl, alkylaminocarbonyS, dialkylaminocarhooyl, earboxy, cyanq, alkyl.th.io, alkylsultuiyl, alkyisulionyl, ammosuifbnyi, alkylaminosuli myL dtalkylarainosul fonyl , alkylsulfonylamino,
- aryiai.kyin means an alky I group, as defined herein, substituted with optionally substituted aryl, as defined herein.
- Optionally substituted cycloaiky means a cycloalkyi group, as defined herein, substituted with one, two, of three groups independently selected from acyl, aeyloxy, acylaraino, optionally substituted alkyl, optionally substituted alkenyl, alkoxy, alkenyloxy, alkoxyearbonyl, alkeny!oxycarhpnyl, alkyl thio, alkyisoitmyi, lkylsulfonyl, arainosuUonyl, slkyiarainostdibnyl, diaikyianiinosulr nyl, a!kylsulfonylamino, halo, hydroxy, amino, aikylamino, diaikylamino.
- alkyl and alkenyl are independently optionally substituted with one, two, three, four, or five halo, e.g. ba!oalkyi, haioaikoxy, haioalkenyloky, or haloaikylsultbnyL
- cyeloafkylalkyF means an -alkyl grou substituted ' with at least one, specifically one or two, optionally substituted cycloalkyi groups, as defined herein.
- Optionally substituted heteroarylalky means an alkyl group, as defined herein, • substituted with at least one, specifically one or two, optionally substituted heteroaryL group(s), as defined herein,
- Optionally substituted heieroc eloalkyr' means a heterocycloalkyl group, s defined herein, optionall ' substituted with one, two, or three sabstituents independently selected .from acyl, acyiarnmo, acyioxy, optionally substituted alkyl, optionally substituted alkenyl, alkoxy, alkenyioxy, halo, hydroxy, alkoxycarbonyl, .
- alkenyfoxyearbonyl amino, alkylamtno., dialkyiarnino, niiro, aminocarbonyl, alkyiammocarbpnyl, ialkylaminoearhonyi carboxy, cyano, alkylthio, alkyisulfmyl, aikyisu!fonyk aminostdfouyL alkylaminosuU nyl, dialkylaminosullbny alkylsulfonylamino. aminoalkoxy, or r l is pentafiuorophenyl. Within the optional substituents on .
- heterocycloa ' lkyi the alkyl and alkenyl, sitter alone or as part of another group . including, for example ' , the- lkyl itv alkoxycarbonyl),. are independently optionally substituted with one, two, three, lour, or five halo.
- Optionally substituted heteroeyclpalkylalkyF' means an alkyl group, as defined herein, substituted with at least one, specifically one or two, optionally substituted
- "Pharmaeeuticai composition” comprises 1) a Compound of Formula ! or a single isomer thereof where the compound is optionally as a pharmaceutically acceptable sal t and .additionally optionally as a hydrate and additionally optionally as a solvate thereof; and 2) a • pharmaceutical ly acceptable carrier, exeipient, or diluent.
- Formula la, lia the following structure .
- Compound A is known by its chemical name N 3- ⁇ [(3 ⁇ [2-ehloro-5 ⁇ methoxy)pIv ⁇
- Yield for each of the reactions described herein is expressed as a percentage of the theoretical yield.
- I009S1 "Patient" for the purposes of the present invention includes humans and other animals, particularly mammals, and other organisms-. Thus the methods are applicable to both human therapy and ' veterinary applications, In a preferred embodiment the patient is a mammal, and in: most preferred embodiment the patient is human.
- an effective amount refers to a sufficient amount of an agent to pro vide the desired biological, therapeutic, and/or prophylactic result. That result can be reduction, amelioration, palliation, lessening, delaying, and/or alleviation of one or more o f the signs, syinpioms, or. causes of a disease, or any other desired alteration of biological system, hi reference to cancer, an effective amount comprises an amount sufficient to cause a tumor to shrink and/or to decrease the growth rate of the tumor (such as to suppress tumor growth) -or to prevent or delay other unwanted cell proliferation.
- an effective amount is an amount sufficient to delay development, in some embodiments, an effective amount is an amount sufficient to prevent or delay recurrence.
- An effective amount can be composition may: (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, retards skrtV t some extent, and preferably stop cancer cell mfiltratkm into peripheral organs; (iv) inhibit (i.e., slow: to some extent and preferably. stop) tumor metastasis; (y) inhibit tumor growth; (vi) prevent or delay occurrence and/or recurrence of tumor: and/or (vii) relieve to some extent one or more of the symptoms associated with the cancer.
- an effective amount may: (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, retards skrtV t some extent, and preferably stop cancer cell mfiltratkm into peripheral organs; (iv) inhibit (i.e., slow: to some extent and preferably
- !3 ⁇ 4i3 ⁇ 4ctive amount for therapeutic use is the amount of Compound A or a metabolite thereof a pharmaceutically , acceptable salt Or solvate thereof, or a composition comprising Compound A or a metabolite thereof or a pharmaceutically acceptable salt thereof, required to provide a clinically significant decrease in the progression of EC,
- At least one therapeutic effect is obtained.
- the therapeutic effect may be a decrease in. the progression of EC as measured by the reduction in tumor size, reduction in metastasis, complete remission, partial remission,, pathologic complete response, increase in overall response rate, or stable disease.
- the improvement of clinical benefit rate is at least about 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, or more,
- a "pharmaceutically acceptable salt" of a .compound means -a salt that is
- Examples of pharmaceutically, acceptable acid addition salts include those formed with inorganic acids such as hydrochloric acid, hydrobromie acid, sulfuric acid, nitric acid, phosphoric acid, and Ihe like; as well as organic aeids such as acetic acid, trifiuoroaeetsc acid, propionie acid, hesanoie acid, cyelopentanepropiomc acid, glyeoiip acid, pyruvic acid, lactic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fiiraarie acid, tartaric acid, citrie acid, ' benzoic, acid, ei iamic acid, 3r(4-hydroxybenzoyl)ben2o.fc acid, niandelic acid,
- a pharmaceutically acceptable base addition salts include those formed when aa acidic proton present in the parent compound is replaced by a metal ion, such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like.
- Preferable salts are the ammonium, potassium, sodium, calcium, and magnesium salts.
- Salts derived from .pharmaceutically acceptable organic non-toxic bases include, but are sot limited to, salts of primary, secondary, and terrfiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic sort exchange resins. Examples of organic bases include isopropy!amme, trimethylamme, diethyiamine, trklhylaniine, tripropylarame, ethanola ine,
- tromethamme A-me iylglucam e, poiyanune resins, and the like- Exemplary organic bases are isopropylarairse, diethyiamine, ethanola rae, trimethyiamin.e, dicyclohexylamine.
- Prodrug "1 refers to compounds that are transformed (typicall rapidly) is vivo to y ield the parent compound of the above formulae, for example, by hydrolysis in blood. Common, examples include, but are not limited to, ester and amide forms of a compound having an active form bearing -a carboxylic acid moiety.
- pharmaceutically acceptable -esters of the compounds of this invention include, but are not limited to, alky! esters (for example with between about one and about six carbons) the alky! group is a
- Acceptable esters als include eycloalkyi esters and aryialky i esters such as, but not limited to benzyl.
- Examples of pharmaceutically acceptable amides of the compounds of this invention include, bat are not limited to, primary amides, arid secondary ami tertiary aSk l amides (for example with between about one and about six carbons).
- Amides and esters of the compounds of the present invention may be prepared according to conventional methods, ⁇ thorough discussion of prodrugs is provided in T, Higachi and V. Stella, "Pro-drugs as Novel .Delivery Systems," Vol 14 of the A.C.S.
- Methodabolite refers to the break-down or end product of a compound or its salt produced by metabolism or biotransformation la the animal or human body; for example, biotransformation to a more polar molecule such as by oxidation, redaction, or- hydrolysis, or to a conjugate (see Goodman and Oilman, "The Pharmacological Basis of Therapeutics” S.sup.th Ed., Pergaiiion Press. Gilman et a-L (eds), 1990 for a discussion of
- the metabolite of a ' Compound of the invention or its salt may be the biologically active form of the compound in the body, hi one example, a prodrug may be used such that the biologically active form, a metabolite, is released in vivo.
- An assay for activity of a metabolite of a compound of the present invention is known to one of skill in the art in light of the present disclosure.
- treating means inhibiting the disease, disorder, or syndrome, that is, arresting its development; ami relieving the disease, disorder, or syndrome, that is, causing regression of the -disease, disorder, or syndrome.
- adjustments 3 ⁇ 4r systemic versus localized delivery, age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by one of ordinary skill in the art.
- Prevention means preventin the disease, disorder, or syndrome from occurring hi a human, i.e. causing the clinical symptoms of the disease, disorder, or syndrome not to develop in an. animal that may be exposed to or predisposed to the disease, disorder, or syndrome but does not yet experience or display symptoms of the disease, disorder, or syiidrome.
- the embodiment includes both the recited compounds as well as individual isomers and mixtures of isomers,
- the embodimen includes the pharmaceutically acceptable salts, hydrates, and/or solvates of the recited compounds and any individual isomers or mixture of isomers thereof, comprises admroistering to a patient: an effective amount o.
- Compound of Formula f or fa or a pharmaceutical, composition comprising a Compound of Formula ⁇ or la,
- methods for treating cancer which method comprises administering to a patient an effective amount of a Compound of Formula 1 or pharmaceutical composition comprising a Compound of Formula 1 where the cancer is EC, in some embodiments, the cancer is T pe 1 EC, In -other embodiments, the cancer is Type IT EC. .
- the Compound of Formula 1 is selected from any of the loUowirig emb diments, including from the Representative Compounds in Table ! .
- W ⁇ W ⁇ , W ⁇ and w are -C(R ) ⁇ where each R 1 is independently hydrogen or alkyl
- R ! is hydrogen.
- R 3 ⁇ 4t> is hydrogen, alkyl, aikenyl, halo, ha!oaikyl, haloaikenyl, hydroxy, alkoxy, alkenyloxy, haloalkoxy, nitrp, amino, alkyiamino, dialkylamino, -HC ⁇ CCOJ-Cs-C ⁇ -alk lene-HiR ' ⁇ 33 ⁇ alky!carbonyL alkenyl.carboayl, carboxy, alkpxycarbonyl. cyano, a!kylthio, -SCOhNR ⁇ 53 , or
- R 5 " and R" ' are iadependentlt hydrogen, alkyl, or aikenyl and R 55a is hydrogen, alkyl, aikenyl, hydroxy, or alkoxy; and all other groups are as defined in the Summary of die Invention, in another ' embodiment, R "li is hydrogen.
- [ 0112) Another embodiment (Q of a -Compound of Formula ⁇ is where 5 ' is hydrogen or alkyl; and all other groups are as defined in. the Summary of the Invention.
- R 3 ⁇ 4 i is alkyl.
- R 5! is methyl, or halo; and ail other groups are as defined in the Summary of the Invention, in another embodiment 32 is hydrogen or fluoro.
- J ⁇ is hydrogen.
- FIG. 1 Another embodiment (E) of a Compound of Formula 1 is where ' 3 is hydrogen, alkyl alkenyl, halo, haloalk l, ludoaSkenyi, hydroxy, aikoxy, alkenyloxy, haloalkoxy, nitro, amino, alkykmino, diaikylamino, ⁇ (3 ⁇ 4 '5 ⁇ )0(0) » ⁇ -0 & -3 ⁇ 6 ⁇ > ⁇ ( ⁇ 33 *) ⁇ * ⁇ ⁇ ⁇ 3 ⁇ 4 ⁇ ⁇ alkenyicctrbonyl, cai'boxy, alkoxycarbemyl, cyano, alkylthio, -S(Q ⁇ NR S5 R 35 * . or
- alkylcarbonyiaffiino where M and R'" b are independent!* hydrogen, alkyl, or alkenyl and R ?3 ⁇ 41 is hydrogen, alkyl, alkenyl, hydroxy, or aikoxy; and all other groups are as defined in the .Summary of the Invention, in another embodiment, is. hydrogen, a!koxy, nitro, amino, or - ⁇ R >s )C ⁇ 0)-C -C ⁇ iky!ene ⁇ ⁇ R >3 )R 3 ⁇ 4iis >.
- si is hydrogen, methox , nitro, amino, or -NHC(0)CH2 ( H.?)2» in another embodiment, is hydrogen or tnethoxy,
- R' is hydrogen, alkyl, alkenyl, halo, haloaikyi, hatoaikenyi, hydroxy, aikoxy, alkenyloxy, haloalkoxy, -nitro, amino, aikylamino, dialkyiamino, -HCR ⁇ C-CQ ⁇ Ci-C alk lene-NiR ⁇ 5 ⁇ , alkylcarbonyl, a!kenylcarhonyl, carbo y, aikoxycarbony), cyano, alkylthio, -SfOja ⁇ 51 ' 2 , or
- R* * is hydrogen, alkyl, aikoxy, or halo.
- R 54 is hydrogen, methyl, meihoxy. bfomo, or chloro.
- K * is hydrogen,, meihoxy, or chloro.
- R Mi , " 2 , and '3 are hydrogen and R t i chloro or meihoxy;
- R 30 , "y and R 3' ' are hydrogen and s '' is m.ethoxy; or
- R 3t ' and R J ' are hydrogen and R " 3 and R >! together with the carbons to which they are attached form
- B is heteroaryi optionally substituted with one, two, or three R 3 .
- B is thico-J-yl, pyrid.ittyi. pyrtm.tdi.nyl, pyridazinyk optionally substituted with one or t o R".
- B is ih.ien-3 ⁇ yi pyrkiin-2- yl, pyridm-3-yi, pyridm- -yl, oxazol-2-yh oxa?.ol ⁇ 4 ⁇ yl ?
- oxaxoi-5-yk isoxazol-3-yI, isoxazol-4 ⁇ yl, isoxazol-5-yL i ida3 ⁇ 4oi-2-yl.
- B ' is thien-3-yl, pyridtn-3-yk pyridm-4-yL isoxazol ⁇ 4 ⁇ yL or pyrazoM-yh each of which is optionally substituted with one or two R " ⁇
- B is pyrid -3-yS, 2-hydroxy-pyri.diri-5-yl, fcoxazo -yl, ⁇ rpyrazoM-yl, each of which is optionally substituted with one r two R ⁇
- 1 ⁇ 4 is cyano; hydroxya ino; carboxy; alkyisui forsyl, ammoalkylo : xy ' ; alkylatttihoalkyloxy; dia!k lamindaikyfoxy; ⁇ N(R 7 jC(0 ⁇ --C.rCiraSkyIene- N(R 7a )R3 ⁇ 4 -C(0)NR3 ⁇ 4 3 ⁇ 43 ; - R3 ⁇ 4fO)R 9il ; :(0)N(R l!) )-C 1 .C i> -aikyie«e. ( ua )R ,i3 ⁇ 4 ;
- 3 ⁇ 4 is:
- R ki is hydroxyamino, -N(R v )C(0 ⁇ -C ⁇ -C ⁇ a!kylene- (R 3 ⁇ 4 )(R 73 ⁇ 4 ) t -C(0)NRR & ⁇ - R"C(0)R 1 ⁇ 2 , *C(O) ⁇ ! ⁇ ')-Cr -aikyieae- (R K,a )R l0b , ⁇ NR- ⁇ (C 11 ⁇ ib , - (R 22 ⁇ e(0)-C C alkyten ⁇ -.NR°C(O)0R S'3 ⁇ 4 ( -N(R !
- each of the alkylene in R 3 ⁇ 4 is independently optionally further substituted with 1 , 2.3, 4, of 5 groups selected from halo, hydroxy, and amino; and all other groups are as defined in the . Summary of the Invention.
- R ia is -!s
- Embodiment (N) provides a compound of Formula I where each R s> is independently halo; eyaao; aiky!; alkenyl; a!koxy; hydroxyamino; carboxy; aikylsulfonyk.
- heter ary! optionally su stituted with one or two ammoatkyk alkylaminoatkyl, or
- each of "the alkylene in 3 is independently optionally further substituted with 1, 2, 3, 4, or 5 groups selected from halo, hydroxy, amino, alkylamino, and dialkykmino; and all other groups are as defined in the Saaunary of the Invention,
- R J is independently halo, a!kyi, hydrox zine,
- each R" is independently methyl, ehioro,
- R 3 is aikyl qr-N(.R ? )C(0)-Ci-C 6 -alky!ene- N(R' 's ) ⁇ R' -b ); and R' is hydrogen or alkyl and R '*a and R 0 are independently hydrogen, a!kyl, aminoa!kyi, a!kylaminoaikyi. or dialfcyianiino alkyl; and all other .groups are as defined in the Summary of the Invention.
- each R -> is independently methyl - HC(0)CH 2 NH(C13 ⁇ 4 - HC(0)CH(CH.v) H 2 , - HC(0)C(CH 3 ) 2 NH2, -NHC(O)- -NHC(Q)CH 2 N(CH -)C3 ⁇ 4CH: fCH3) 3 ⁇ 4 or -NHC ⁇ 0)CI3 ⁇ 4CHj)NH(CH s ).
- R 1 of embodiment R, R 51 ', R ' ⁇ , and R ! are hydrogen and R i:! is halo or alkoxy; R 5l! ,.
- R > % and R'* ' are hydrogen and R s ⁇ is aikoxy: or R > ⁇ ! and R* are hydrogen and R ? ! and R J " together with the carbons to which they are attached lorn* a 6 ⁇ meinbered heteroaryl; and all other groups are as defined in the Summary of the .Invention.
- R ', R* 2 , and iV " * are hydrogen and R is halo or alkoxy; or R ? ⁇ R J ⁇ and R'" are hydrogen and R ? A is alkoxy.
- the compound of Formula I is a compound of Formula la;
- R is methyl
- R ⁇ ⁇ is hyd ogen
- R" is hydroge or alkoxy
- R '"4 is hydrogen, alky i, alkoxy, or halo; or R > and R* 4 together ' with th carbons to which they are ⁇ attached form a 6-memimred heteroaryl; and
- IV is hal or methyl
- 3 ⁇ 4 is -NC ⁇ yCfOi-C C ⁇ alk i . ert ⁇ NiR. ⁇ KR 51 ') .
- R. 7 is hydrogen and R 7a and d it Iky ⁇ am moa I ky l .
- R >! is methyl; and R >( ⁇ R " , and R. > arc hydrogen and R ' is halo or alkoxy or R : ⁇ i > R ' ⁇ and R 3 ⁇ 4i are hydrogen and 3 ⁇ 4 - is aikoxy; or a single stereoisomer or mixture of stereoisomers thereof.
- R "iS is - HC(0)CH 2 NH£G%k -NHC(0)CH(CH>)NH 2> - HC.(G)C ⁇ C3 ⁇ 4)2NH2, -NW €(0)-CHlN ⁇ CH3) 2 ,-NHC(e)CM 2 N ⁇ CH5)CH 2 CH 2 ⁇ CH 3 )2,-- HC(0)eH(NH2)GH 2 €H 3s - HC ⁇ 0)C3 ⁇ 4 (CH3 . )CH 2 CH 2 N ⁇ CH3)2 5 or - HC ⁇ 0)eHC3 ⁇ 4)NHfC3 ⁇ 4).
- the compound of formula la is:
- R ! in the compound of formul II is hydrogen, optionally substituted alkyl, optionally substituted eycloaikyl, optionally substituted eycioalkylaiky optionally " substituted aryi, optionally substituted arylalkyl, optionally substituted
- heteroeycloalkyl optionally substituted heteroeyeloalkylalkyl, optionally substituted heteroaryl or optionally substituted heteroaryialkyi.
- R f is ydrogen, optionally substituted alkyl, optionally substituted eycloaikyl, optionally substituted arylalkyl, or optionally ⁇ .substituted heteroeycloalkylalkyl.
- R l is hydrogen, alkyl alkyl substituted with one or two hydroxy, alky! substituted with alkoxy, eycloaikyl, arylalkyl, or heterocydoaikylalkyi.
- R 1 is hydrogen, methyl, ethyl, propyl isopropyL ' 2-hydroxypr pyl, 3-hydtoxypropyl, 2-ethoxyethyL S-rneihoxypropyi,
- R ! is ethyl, ssopropyi, eyclopentyi, or cycSohexyl
- ! is ethyl
- R is hydrogen or alkyl where the alkyl is optionally substituted with 1, 2, 3, 4, or 5 R 3 ⁇ 4 groups.
- R 2 is hydrogen or alkyl where the alkyl is optionally substituted with one, two, or three groups, More specifically, R " is hydrogen or alkyl where the alkyl is optionally substituted with one, two, or three * groups; and each R ⁇ when present, is independently selected. tem amino, alkylamino, dialkylainino, and halo.
- R* is hydrogen, methyl, ethyl, propyl, isopropyl, ierr-butyi, -aniiiio propyl -( ' A' ' ⁇ met!rj'lamlno)-propyL 3- ⁇ N,/V- ⁇ li8ieihybmmo)-pr0pyl y 2 iluoroethyl, or 2,2,2 -triOuoroetliyl
- R' is hydrogen or ethyl. Yet even more preferably.. R ' is ethyl
- R " is hydrogen .
- R is optionally substituted alkyl.
- R 4 is methyl or ethyl. More specifically, is methyl. more specifically, R i; is acetyl
- R i! is phenyl optionally substituted with 1 , 2, 3, , or 5 R v groups.
- R° is: phenyl optionally substituted with one or two R ' groups; and each R: ⁇ when present, is independently selected from aryL halo, alkoxy, aryloxy, and hakralkyl. More specifically, .
- R* 1 is phenyl optionally substituted with one or two R 9 groups; and each R !> , when present, is independently selected rom phenyl, iluoro, chloro, meihoxy, pheny!oxy, and mfiuo.romelhyl Eveu more specifically, R' f is phenyl, phenyl substituted with phenyl,, fluorophenyl, difluorophenyl, c orophenyS, diehlorophenyl, phenyl substituted with chloro and fluoro, terrorismhoxyphenyhdiuiethoxyphenyL phetiyloxypheoyi, or triflupro.raethylphenyl.
- W is hctere>ary! optionally su stituted with I, 2, 3, 4, or 5 R v groups.
- 6 is a ⁇ -membered .heteroaryi optionally substituted with one or two R ⁇ . More specifically, R* is pyridlnyl, pyrazinyl, pyrirnidinyl, or pyridaxmyi each, of which is optionally substituted vvith one R wherein R when present, is halo.
- R° is pyridm-2-yl, pyridin-3-yl, pyridiB-4-yl 3-0aoropyiidm-4-y!, pyraziii-2-yl, pyrazm-3-yl, pyri.raidin-2-y!, pyrimidra-4-yl pyrimidin-5-yL pyridazin-3-yL or pyridazm-4 ⁇ yl, each of which is optionally substituted with one or two R .
- R* is pyrazmyl, pyrirnidinyl, or pyridazirryl, each of which is optionally substituted with one wherein R ⁇ when present, is halo. Even more specifically, . R is pyrazin-2-y!, pyrazin-3-yi, pyi'iniidin-2-yi, pyrimidra-4-yL pyrimidm-S-yl, pyrklazin-3 -yl, o p ridazin-4-y 1.
- R* is a 5-membered heteroaryi optionally substituted with one or two R '? .
- R f! is pynm>lyl y imidszolyl, thien l, ihiaxolyl, oxazoiyl,
- R (> is pyrazpH-yL pyriszol-3-yl, pyraza1-4-yS, pyrazol-S-yi, U idazol- I-yL irnidazol-2-yi, imit!azol-4-yi, imidazoi-S-yl, thieti»2 ⁇ yl, thien-3- yl, tbiazol-2-yl, thiazoM-yb thiazol ⁇ 5-yL oxazo!-2-yI, oxazoM-yl, oxazol-5-yi, isoxazol-3- yi, isoxazoM-yi, ispxazoi-S-yi, UJ ⁇ xa iazoM- L J-oxadiazoi-S-yi I 3 t 4-oxadiazol-2- yi, 1 ,2,4-oxadiazol-3-yL l ,2,4-
- R y when present, i methyl, benzyl, cyano, phenyl, A ⁇ eri-hutoxycarbonyl, or chloro. Even more specifically, is pyrazoi-3-yb pyraxol- 4-yl, pyrazol ⁇ 5 ⁇ yl, iniidazol-2-yl, imidazol-4-yi, imidazol-5-yl, ihien-2-yl, . ihien-3-yl,. iliiazoi-
- R ' ' when present, is methyl, benzyl, cyano, phenyl, ⁇ '-fert-butoxycarbonyl, or ehioro.
- R (> is tlueayl, pyrroiyl, luranyl, pyrazoiyl, thiazoiyi, isoxazolyVimidazolyi, triazoiyS, or tetrazoiyi, each of which is optionally substituted with one R ' wherein K 5 ', when present, is methyl, benzyl, cyano, phenyl, A ? -ieri-buioxyearbonyl, or e mindo.
- R" is thien-2-yi, thicn ⁇ 3-yl, pyrrol-2 ⁇ yi, 3 ⁇ 4ran-2-yl, rurasi-3 ⁇ yl, pyrazoi-3- vL pyraZol-4-yL pyrazol-5-yl, tliiazol-2-yL tbiazol-S-yl isoxazoi ⁇ 4-yl, sniidazohS-yi, tria3 ⁇ 4ol-
- R" is thieri-2-yl thien-3-yl, .
- 5-cyano-thien-2-yl s 4-meihvl-Chien-2-yi, 4-methyl- tliien ⁇ 3-yl, 5-chloro-thien-5-yb 5-phenyi-ihien-2-yI, pyrrol-2-yl- A-ie/ -butoxycarbonyl- pyrrol-S ⁇ yl, N-methyl-pyo3 ⁇ 4l ⁇ 2-yi, furan-2-yi, iuran-3-yl, pyrazol-a-yi, pyra ol-4-yi, ⁇ V- benzyl-pyrazol-4-yi, pyrazol-5-y.l, thiazol-2-yI, thiazoi-5-yl, isoxazol-4-y!, imidazol-5-yl, iriazol-5-yi, or tetrazo
- R* is ihien-2-yl, ihi ii-3-yl, pyrrol ⁇ 2-yl s . furan-2-yi , furan-
- R b is indoi-2-yl, mdoi-3-yl, indol-4-y!, indoI-5-yl, mdol-6-yl indoi- 7-yl, benzirnidazol-2-yl, benximidazol- -yl, benzimidazol-5-yL ben3 ⁇ 4imidazol-6-yi, henzsmtdazol-T-yi, henzo teri-l-yl, benzoitmm-3-yi
- R s is hydrogen, optionally substituted alkyl, optionally substituted cycloailcyi,- optionally substi uted ' heferoeycloalkylalkyl, or optionally substituted aryialky!;
- X is -NH- ' R 2 is hydrogen or alky), where the alkyl is optionally substituted with one or two R* groups;
- R '! is alkyl;
- R* is hydrogen: R* is phenyl or heteroaryl wherein the phenyl and heteroaryl are optionally substituted with one.
- each R ⁇ when present is independently amino, alfcylami.no, dialkylamtno, or halo; and each R ⁇ when present, is independentl alkyL arylalkyl, cyano, aryl, alkoxycarbonyl, or halo.
- R* is pyrazol-3-yl, pyra3 ⁇ 4ol- -yl, pyrazo! ⁇ 5-yl, iinidazoi-2- yi, kn.idazol-4-yS, imidaz(il-5-yL thien-2-yl, thien-3 ⁇ yi, thiazoi-i-yi, thiazpl-4-yI, thiazoi-S-yl, oxazol-2-yl, oxazol-4-yt.
- oxazoi-5-yi isoxazo!-S-yL isoxaxo -yl, isoxazol-5-yi, 1 ,2,3- oxadiazol-4-yl, 1 : 2,3 ⁇ oxadiazo!-5-yi 1 ! .3,4-o. adiazol-2-yi, .1 ,2,4-oxadiazoi-3-yl, 1 ,2,4- oxadiazol ⁇ 5-yi, aran-2-yl, iiiran-3-yl, pyrro! ⁇ 2-yi, pyiTol-3-y . triazo!-4-yi, triazol-5-yl, or tetraxol-S-yl; each of which is optionally substituted with .1, 2, 3, 4, or 5 R. 9 groups,
- R 1 is alkyl or eycioalky!; R 4 is methyl; and R" is heteroaryl optionally substituted with one or two R* groups.
- each R* when present, is independently alkyl, arylalkyl, cyano, aryl, alkoxyearbon l, or halo.
- pyrazol-3-yl is pyrazol-4-yJ, pyrazol-5-yk inmiazo.l-2-yl, imidazol-4-yl, imidazol-5-yl, thieu-2-yi, thien-3-yl, thiazol-2-yl, thiazo -yl, thiazol-5-y.l, oxazol-2-yi, oxazol-4-yl, oxazol- S-yi isoxazoi-3-yL isaxazol- -yl, ssoxazoi-S-yl, i ,2,3-oxadiazol-4-yi, l ,2,3-0.xadia20l-5-y!, l,3.4-'Oxadiazoi"2-yL 1 ,2, -oxadia2oi ⁇ 3 ⁇ y[, l,2,4-0xadiazo1-5-yl, furan-2-yl, furaa-3
- R" is hydrogen
- R ⁇ is methyl or ethyl. optionally substitut d with, one or two 11 ' groups. Specifically each R ⁇ when, present,, is: independently h.aio, alkoxy, or haloalkyl.
- R ! is alkyl or eye!oaiky!; ⁇ is methyl; and R is hydrogen.
- R 1 is alky! or c cloalkyl
- R 4 is methyl
- R * is optionally substituted alkyl
- the compound of formula 1 is a compound of formula ⁇ A .
- R ! is alkyl, cycloalkyl, cyeloaikylaikyl, aryl. arylalkyl, heterocycloalkyl,
- R" is hydrogen or alkyl
- R " * is alkyl
- R '" is hydrogen
- R 3 ⁇ 4 is phenyl, acyi or heieroaryi the phenyl and h teroaryl are is optionally substituted with L 2, 3 ⁇ , 4, or 5 R ' * groups;
- each R ' ⁇ when present, is independently halo, alkyl, haloalkyl, alkoxy, haloalkoxy* eyano, atatpp, aikylamino,. dialkylamino., alkoxyalky!, earhoxyalkyl, aikoxycarbotiyl, aminoa!kyl, cycloalkyl, aryl, arylalkyl, aryloxy.
- heieroeycloalkyl or lieteroaryl and where the cycloalkyl, aryl heteroeyclo Sky],, and heieroaryi, each either alone or as part of another group within R" are independently optionally substituted with 1 , , 3, or 4 groups selected from halo, alkyl, haloalkyl, hydroxy, alkoxy, haloaikbxy, amiao, alkyiami.no, and
- R ! is alkyL cycloalkyl, heteraeycloalkylalkyL or arylalkyl;
- R " is hydrogen or alkyl;
- W is afky :
- R* is hydrogen;
- R*-' is phenyl or heteroaryl wherein the phenyl and heteroaryl are isjjptionally substituted with one, two, or three R groups;.
- R is methyl.
- ! is aikyl.
- each R 9 when present, is independently a kyl arylalky!, cyano, aryj, alfcoxycarbonyl, .or halo.
- R" is pynizoiyl, imidazolyt thienyi, thiaxoSyl, oxazolyl, tsoxazol l, oxadtazolyl, ftsranyl, pyrroiyi, iriamlyl, or tetraxoiyl; each of which is optionally substituted with i , 2, or 3 v groups,
- R. 6 is pyi3 ⁇ 4zo]-3-yl t pytazot- ⁇ yl, pyrazoh5-yi, inikiazoj-2 ⁇ yl, i ida «0 4-yl, ii «idazo!-5- I, Uueft-2-yI, dvieu ⁇ 3 ⁇ vL thiaz0i ⁇ 2-yl, thiazoS-4-yl.
- R fi is pyraziny pyrimidiayi or py idaziny! each of which is optionally substituted with 1, 2, or 3 R y groups and R' is methyl.
- K is hydrogen
- IV is methyl
- R 1 is optionally -substituted alkyl, eycloalkyl or heteroeyeloaikyl
- " is heteroaryl optionally substituted, with ⁇ . 2, or
- the compound of formula Ha is selected form:
- the compound of formula HA is Compound B, which is
- the invention provides a method of treating endometrial carcinoma in a patient, comprising administering, to the patient an. dfeetive amount of Compound A, or Compound B.
- Compound A or B is administered as a capsule or tablet pharmaceutical composition.
- the amount Compound A or in the tablet or capsule formulation is sufficient to produce saturation of absorption administered once. daily.
- about 10.0 mg to about 800 mg Compound A is administered as a capsule composition once daily.
- composition once daily.
- Compound A or B is administered as a capsule, composition once daily.
- about 100 mg to about 800 mg Compound A or B is administered as a- tablet compbsi Hon once daily. administered as a tablet composition once daily.
- Compound A or B is administered as a tablet composition once daily.
- the endometrial cancer is ' advanced or recurrent.
- Compound A or B is administered as a capsule consisting of Sua 0 capsules filled with drug substance only. There are no additional exespients other than the capsule gelatin and coloring agents.
- the composition -of the hard gelatin capsule shell and color demarcation, are presented in. the table below.
- Compound A or B is administered as a 100, i 50, or 200 tog tablet.
- the tablet strength will be distinguishable by shape and/or size.
- the tablet formulation contains ' Compound A, silk fied. aiicracrystailme cellulose, partially
- Ail three tablet strengths are manufactured from a • common blend with the composition listed in the 3 ⁇ 4 flowing Table.
- the effective amount of Compound A ' or B that is administered in the metiiod produces at least one therapeutic effect selected fom the group consisting of reduction in size of a tumor, reduction in metastasis, complete remission ⁇ partial remission, stable disease, increase in overall response rate, or a pathologic complete response.
- the improvement of clinical benefit rate is about 20 percent or higher.
- the therapeutic effec is an increase in overall response rate.
- the increase in overall response r te is about 10 percent or more or higher.
- CBR clinical benefit rate
- the improvement of clinical benefit rate is a least about 20 percent or higher.
- a comparable clinical benefit rate (CBR - CR (compiete remission) + PR (partial- remission) + SD (stable disease) > 6 months) ts obtained with treatment of Compound A or a pharmaceutically acceptable salt thereof .
- the impro ement of clinical benefit rate is at least about .20 percent or higher.
- the invention provides a method for treating breast cancer in a.. patient in need of such treatment* .comprising administering to the patient an effective amount of (A) ietroKole in combination with or a. pharmaceutically acceptable salt* ⁇ dutiom.ec,. hydrate, of solvate ' thereof; or (B) !etrozofe in combination with
- th method comprises at least one cycle, wherein die cycle is a period of 4 weeks, wherein for each cycle in (A) the ietrozole is administered at a daily dose of about 2.5 mg and the Compound A is administered at. a daily dose in tablet form -of 400 rag; and
- the breast cancer is hormone receptor-positive (ER- and/or POR ⁇ .
- HER2-negaisve (HER2-) breast cancer which is refractory to a nonsteroidal aromatase inhibitor.
- the breast cancer is hormone receptor-positive (ER ⁇ and/or PGR ⁇ , RER2-negative (HER2-) breast cancer which is refractory to a nonsteroidal aromatase inhibitor and the . effective amount comprises a combination of leirozoie . and
- the breas cancer is hormone receptor-positive (ER+ and/or PGR+), HE3 ⁇ 42 -negative. (HER2--) breast cancer which is refractory to n nonsteroidal aromatase inhibitor and the effective amount eornprises a combination of letrozo!e and Compound B. therapeutic effect selected from the group consisting of reduction in size of a tumor,
- the effective amount produces an improved clinical benefit rate (CBR) according to the equation CBR ⁇ CR (complete
- the improvement of clinical benefit rate is one or ail of (i) about 20 percent or higher; (ii) the: therapeutic effect is an increase in overall response rate;
- the invention provides a composition for use in treating breast cancer in a human patient., t e composition comprising a clinically proven safe and efiee live amount of letrozoie and either Compound A or a pharmaceutically acceptable salt thereof, o Compound B or a pharmaceutically acceptable salt thereof.
- the leirozole is formulated for a daily dose of 2,5 nig.
- the letrozoie is formulated for a daily dose of 2.5 nig and the Compound A is formulated as a tablet for a daily dose o 00 mg.
- the letrozoie is formulated for a daily dose of .2.5 mg and the Compound B as a table for a dose of 50 mg twice daily.
- the invention provides a kit comprising a dose of (A) letrozoie and a. dose of either Compound A, or a pharmaceutically -acceptable salt thereof, or Compound B or a pharmaceutically acceptable salt thereof
- the kit comprises instructions for using the letrozoie, as well as the Compound A or
- the invention provides a method of treating breast cancer in a patient in need of such treatment, comprising administering to the patient an effective amount of !etroxole in combination with Compound A.
- the Compound A is administered as a capsule or tablet pharmaceutical composition.
- tire amount of Compound A is sufficient to produce
- about 200 mg to about 700 mg Compound A is administered as a capsule composition once daily.
- Compound A is administered as a tablet composition onee daily.
- Compound A is -administered as a capsule consisting of Size capsules filled with drag substance only. There are no additional excip&nls other than the capsule gelatin and coioring agents.
- the composition of the hard gelatin capsule shell and color demarcation are presented in the table below.
- Compound A is administered a a 100, I SO, or 200 mg tablet.
- the tablet strength will be distinguishable b shape and/or size.
- the tablet formulation contains Compound A, siiieified macrocrystalline cellulose, partially pregeiatinized maize starch, sodium starch glyco te, hypromcUose, colloidal silicon dioxid stearic acid, and magnesium stearatc. All three tablet strengths are manufactured from: a common blend with die composition listed in the following Table.
- the invention provides a method of treating breast cancer in a patient in need of such treatment, comprising . .administering to the patient an effective amount of letroxole in combination with Compound..8 ⁇ ,
- the Compound B as a capsule or tablet pharmaceutical composition.
- the ' amount of Compound Bin th tablet or capsule formulation is sufficient to produce saturation of absorption when administered once daily.
- f.O02 i ⁇ jij the amount of Compound B in the tablet or capsule formulation is sufficient to produce saturation of -absorption when administered twice daily.
- 00217 j about 10 mg to. about 100 mg Compound B is administered as a capsule composition twice daily.
- Compound 8 is administered as a capsule composition twice daily.
- Compound B is administered as a capsule composition twice daily.
- composition twice daily in another embodiment, about 30 mg Compound B is administered as a capsule composition twice daily. composition twice daily.
- Compound B is administered as a capsule composition twice daily,
- Compound 8 is administered as a capsule composition twice daily.
- Compound A is administered as a capsule consisting of Size-0 ca sules filled with 10. 30 or 40 m of drug substance only. There are no additional excipients other than the capsule . gelatin ' and coloring agents. The composition of the hard gelatin capsule shell and color demarcation are presented in the table below.
- the invention provides pharmaceutical compositions comprising an inhibitor of the PDRs of Formula I or II and a pharmaceutically acceptable carrier, exeipiem, or diluent.
- administration is by site oral route.
- Administration cau be, for example, orally, .nasally, parenteral ly (intravenous, intramuscular, or subcutaneous), topically, transderoaliy, mtravaginaiiy, iiitravesicaliy, intracistemaliy, or reetaliy, in the form of solid, semi-solid, lyophilized powder, or liquid dosage forms, such as for example, tablets, suppositories, pills, soft elastic and har -geiada capsules, powders, solutions, suspensions, or aerosols, or the like, specifically in unit dosage forms suitable for simple administration of precise dosages.
- compositions will include a conventional pharmaceutical carrie or exeipient and a Compound of Formula I or If as the/an. ac tive agent.
- Adjuvants include preserving, wetting, suspending, sweetening, flavoring, perfuming, emulsifying, arid, dispensing agents. Prevention of the action of microorganisms can be ensured by various antibacterial and -antifungal agents, for example, pant bens, ehforobmanoi, phenol, sorbie acid, and the like. It may also be desirable to include isotonic agents, .for example sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form ean be brought about by the use of agents delaying absorption, for example,, aluminum monostearate and gelatin.
- a pharmaceutical composition of the invention may also contain minor amounts of auxiliary subs tances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorts-tan uioiioUuiraie, triethanolamine oleate, butylaled hydroxytoluene, etc.
- auxiliary subs tances such as wetting or emulsifying agents, pH buffering agents, antioxidants, and the like, such as, for example, citric acid, sorts-tan uioiioUuiraie, triethanolamine oleate, butylaled hydroxytoluene, etc.
- the choice of formulation depends on various factors such as the mode of dru administration (e.g., for oral administration, formulations in the form of tablets, pills or capsiil.es) and the bioavailability of the dru substance.
- pharmaceutical formulations have been developed especially for -drugs that show poor bioavailability based upon the principle thai bioavailability can be increased b -increasing the surface area i.e., decreasing panicle size.
- U.S. Pat. No.. 4, 107,288 describes ⁇ . pharmaceutical formulation having particles in the size range from 10 to 1 ,000 ran in which the active material is supported on a crossl inked matrix of macromoleeuies. li.S.
- Pat, No, 5, 145,684 describes the production of a pharmaceutical formulation in which the drug substance is pulverized to nanoparticles (average particle size of 400 am) in the presence of a surface modi bomb and then dispersed hra liquid medium; to give pharniaceutical ibnmiiation that exhibits remarkably high bioavailability, acceptable sterile aqueous. r nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitute ri into sterile injectable solutions or dispersions.
- aqueous and nonaqueous carriers examples include water, etlianol,. polyols ipropylenegiyeol, poiyethyie.neglyeol., glycerol, and the like), suitable mixtures thereof, vegetable oils (such s olive oil) and injectable organic esters such as ethyl oleate.
- etlianol etlianol
- suitable mixtures thereof examples include vegetable oils (such s olive oil) and injectable organic esters such as ethyl oleate.
- vegetable oils such s olive oil
- injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of a coating such as leci thin, by. the maintenance of the required particle
- One specific route of administration is oral, using a convenient daily dosag regimen that can be adjusted according to the degree of severity of the disease-state to be treated.
- Solid dosage forms for oral administration include capsules, tablets, pill ' s, powders, and granules.
- the active compound is admixed with at least one inert customary excipient (or carrier) such as sotf ium. citrate or dicaieium phosphate or (a) .fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol.
- binders as for example, cellulose derivatives, starch, aiignates, gelatin, polyvinylpyrrolidone, sucrose, and gum acacia,
- hismeetants as for e ample ; , glycerol
- disintegrating agents as for example, agar-agar, calcium carbonate, potato or tapioca tarch, alginie acid, erosearme ' Hose sodium, complex silicates, and sodium carbonate, (e).
- solution retarders as for example paraffin
- accelerators as for example, quaternary ammonium compounds
- wetting agents as fo example, cetyl alcohol, and glycerol monostearaie.
- magnesium stearate and the like adsorbents, as for example, kaolin and beuionite, and lubricants, as for example, tale, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium laaryl sulfate, or mixtures thereof.
- the dosage forms may also comprise buffering agents.
- Solid dosage forms as described above can be prepared with coatings ami shells, such as enteric coatings and others well known in the art. They may contain pacifying agents, nd can also be of suc /composition thai -they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedded compositions that can be used are polymeric substances and waxes.
- the active compounds can also be in microencapsulated- orm, if appropriate, with one or more of the above-mentioned exeipients, 002381
- Liqu id dosage forms ib ' r oral • administration include pharmaceutically acceptable emulsions, solutions,, suspensions, syrups, and elixirs.;
- Such dosage orms are prepared, for pharmaceutically acceptable, salt thereof,. and optional, pharmaceutical adjuvants in a carrier, such as, for example, wate , .saline, -aqueous dextrose,- glycerol, ethanol and the like;
- solubilizmg agents and emulsifiers as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benfc l alcohol, -.benzyl benxoate, propylenegiyeoL
- .oils in particular, cottonseed oil, groundnut oil, com germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrot rftayl alcohol,
- Suspensions in addition to the active compounds, may cont in suspending agents, as for example, ethoxyiated isostearyl alcohol s3 ⁇ 4 pojyoxyethy e sorbitol and sotbiian esters, krocrystallme cellulose, aluminum metahydroxide». bentonite, agar-agar and tragaca th, -or mixtures of these substances, and the like.
- suspending agents as for example, ethoxyiated isostearyl alcohol s3 ⁇ 4 pojyoxyethy e sorbitol and sotbiian esters, krocrystallme cellulose, aluminum metahydroxide». bentonite, agar-agar and tragaca th, -or mixtures of these substances, and the like.
- compositions for rectal administrations are, for example, suppositories that can be prepared by. mixing the compounds of the present invention with for example suitable non- irritating exeipients or carriers such as cocoa butter, poiyetbyleneglycoi or a suppository wax, which are solid at ordinary temperatures but liquid at. body .temperature and therefore, melt while in a suitable- bod cavity and release the active component therein.
- suitable non- irritating exeipients or carriers such as cocoa butter, poiyetbyleneglycoi or a suppository wax, which are solid at ordinary temperatures but liquid at. body .temperature and therefore, melt while in a suitable- bod cavity and release the active component therein.
- Dosage forms for topical administration of a compound of this invention include ointments, powders, sprays, and inhalants.
- the active component is admixed under " sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propelkmts a ⁇ may be required.
- Ophthalmic ibnnulations, eye ointments, .powders, and isolations are also contemplated as being within the scope of this invention.
- Compressed gases may be used to disperse, a compound of this invention in aerosol form.
- Inert gases suitable for this purpose are nitrogen, carbon, dioxide, etc.
- compositions will contain about 1 % to about 99% b weight of a compound(s) of the invention, or a phannaceutically acceptable salt thereo f, and 99% to .1% by weight of a suitable pharmaceutical exeipient.
- the composition will be between about 5% and about 75% by weight of a eonipound(s) of the invention, or a
- the compounds of Formula ⁇ or la, or their pharmaceutically acceptable salts or solvates are administered in art .effective amount which will vary depending upon a variety of factors including the activity of the specific compound employed, the metabolic stability and. length of action of the compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drag combination, the severity of the particular disease-states, and the host undergoing therapy.
- the compounds of Formula i or 0. can be administered to a patient at dosage levels in the range of about ( ) , 1 to about 1 ,000 mg per day, or i the range. of 100 mg to SCO mg per day, orin the range of 200 to 700 mg per day, or in the range of 300 t 600 mg per day,
- a dosage in the range of about 0.01 to about 1.00 rng per kilogram of body weight per day is an example.
- the specific dosage used can vary.
- the dosage can- depend on a number of factors including .the requirements of the patient, the severity o f the condition being treated, and- the pharmacological activity of the compound being used.
- the determination of optimum dosages fo a particular patient is well known to one of ordinary skill in the art. If formulated as a fixed dose, such combination products emplo the compounds, of this invention within the dosage range described above and the Other
- Compounds of Formula i or H may alternatively be used sequentially with known.pharraaceutically acceptable agent(s) when a "combination formulation is inappropriate.
- the effective amount produces at least one therapeutic effect selected from the group consisting of reduction in size of a tumor, reduction in metastasis, complete remission, partial remission, stable disease, increase in overall response • rate, or a pathologic complete response.
- the effec tive amount produces an improved clinical benefit rate (CBR ⁇ CR (complete ' remission) PR (partial remission) * SD (stable disease) > 6 months), in some embodiments, the improvement ' of clinical benefit rate is about 20% or higher. In some embodiments, the improvement of clinical benefit rate is at least about " 20%, 30%, 40%, 50%, 60%, 70%, S0%, or more.
- the therapeutic effect is an increase in overall response rate. In some 70%, 803 ⁇ 4 or more,
- the improvement of clinical benefit rate is at least about 20%, .In some embodiments, the improvement of clinical benefit rate is at least, about 30%. in some embodiments, the improvement of clinical benefit rate is at least about 40%. in some embodiments, the improvement of clinical benefit rate is at- least about 50%. in some embodiments, the i pr v ment of clinical benefit rate is at least about 60%, in some embodiments, the improvement of clinical benefit- rate is at least.abo ' ut 70%. In some embodiments, the improvement of clinical benefit rate is at. least- bout 80%,
- a comparable clinical benefit rate (CBR— CR (complete remission) + PR (partial remission) 4 ⁇ SD (stable disease) :6 months) is obtained with treatment of a) Co poun A or B or a pharmaeeuticaily acceptable salt thereof.
- the improvement of clinical benefit rate is at least about 20%.
- the improvement of clinical benefit rate is at least about 30%.
- the improvement of clinical benefit, rate is at least about 40%,
- the improvement, of clinical benefit rate is at least about 50%.
- the improvement of clinical benefit rate is at least about 60%.
- die improvement of clinical benefit ate is at least about 70%.
- the improvement of clinical benefit rate is at least about 80%.
- the starting -materials and she intermediates of the reaction- may be isolated and purified: if desired .using conventional techniques, including but not. limited to filtration, distillation, erystailiz3 ⁇ 4ti6r-,. chromatogra hy and the like. Such materials may he characterized using conventional means, including physical constants and spectral data.
- the compounds of the invention may have asymmetric carbon atoms o quatermzed nitrogen atoms in thei structure.
- Compounds of Formula I that may be prepared through the syntheses described herein may exist as single stereoisomers, racemates, and -as mixtures of enantiomers and dtastereoniers.
- the compounds may also exist as geometric- isomers. Ail such single stereoisomers, raeemates find mixtures the eof, and geometric isomers are intended to be within, the scope of this invention.
- om of the compounds of the.- invention may exist as tautomers.
- the molecule may exist in the ' euol form; where an amide is present, the molecule may exist as the iuiidle acid; and where an enamine is present, the molecule ma offers a inline. All such tautomers are within the -scope of the invention, and to the extent that one structure is used to depict a compound, it includes all such
- ring-B in can be 2- hydroxy-pyridmyi, also described as its structure:
- Compound A-2 is named N-(3 ⁇ i[(2Z) ⁇ 3 ⁇
- iaiitomeric forms can mt rconvett
- mterconverskm can also exist between the uncharged tautomeric forms and the xwitterionic forms.
- each taiiiomcr or KwittcrioTJ is included withi herein, the structure
- the present invention also includes -oxide derivatives and protected derivatives of compounds of Formula f.
- the nitrogen atom can be converted to an N-oxide by methods well known in the art.
- compounds of Formula I contain groups such as hydroxy, earboxy, thiol, or any grou -.containing a - nitrogen aiomfs), these groups can be protected with a suitable "protecting group” or "protective group," A comprehensive list of suitable protective Softs, I nc. 19 1 , the disclosure o f which is incorporated herein -by reference in its entirety.
- the protected derivatives of compounds of Formula I can be prepared b methods well known in the art.
- stereoisomers f rom raeemic mixtures or son-raeemie mixtures of stereoisomers are well, known in the art.
- -optically active (R.) ⁇ and (S)- isom r may be prepared usin chirai sytuhons or chirai reagents, or resolved using conventional techniques
- Enantiomers (R- and S-isome t s ⁇ may be resolved by methods known, to one of ordinary skill in. the art.
- i niz ti n ofdiastereoisorrierie salts or complexes which may be separated, for example, by-crystallization; via formation of diastereoisomenc derivatives which may be separated, for example, by crystallisation, selective reaction of one enantiomer with an enautiomef" specific reagent, for example enzymatic oxidation or reduction, followed, by separation of the modified and unmodified enantiomers; or gas-liquid or liquid
- enantiomeric form Alternatively, specific enantiomer may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents or by converting on enantiomer to the other by asymmetric transformation.
- enantiomers enriched in particular enantiomer, the major component enautiorner may be further enriched (with concomitant loss in yield) by reerystei!ization.
- the compounds of the present invention can exist in unsolvated a well as solvates.) forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. In general, the soivated forms are considered equivalent to the unsolvated forms for the purposes of the present invention.
- an intermediate of formula- 3 can be prepared by ' briefly !ieating an appropriateiy substituted quinoxalmc (for example, commercially available 2,3-diehioroq:uino aliiie) and an appropriately substituted sulfonamide of formula 2 are -c mmereiaUy available or can be prepared by one of ordinary skill in the art), a base sueh as K2CO5, in a solvent, such as DMF or DM SO. Upon completion (about 2 hour ' s), the reaction mixture is then poure into water and followed by 2 N HCI.
- an appropriateiy substituted quinoxalmc for example, commercially available 2,3-diehioroq:uino aliiie
- an appropriately substituted sulfonamide of formula 2 are -c mmereiaUy available or can be prepared by one of ordinary skill in the art
- a base sueh as K2CO5 in a solvent, such as DMF or DM SO.
- the product is then extracted into a solvent such as ethyl acetate nd washed with water and brine.
- a solvent such as ethyl acetate nd washed with water and brine.
- the organic layers are combi ed and dried over a drying agent sueh as sodium, sulfate, filtered, and concentrated under -vacuum to provide a compound of formula 3.
- LG is a leaving group such as ehloro.
- Compound 5 is reacted with NH J ' or where R 8 and R° are independently hydrogen or alkyi. The reaction, is carried out in die presence of a base, such as KMCO3, in a solvent such, as DMF.
- reaction is carried out in the presence of a base such as Naff in a solvent such as DMF.
- R' is as defined in the Summary of the Invention:
- R SSa where R i8 , K ⁇ and R , are as
- HOC(0)-CrC is -aik ⁇ lene.N(R !S3 ⁇ 4! )C(O)R i * a ;
- NiR ' ⁇ R* The reaction, is carried oui under standard- amide coupling conditions known to one of ordinary skill in the art. In particular, die reaction is earned out in the presence of a coupling ageat such as I!ATU. a base such as DFEA, and in a solvent such as 0MV. Where applicable, the -proieciing group is then removed using procedures known to one of ordinary skill . in the art, such as treating with acid where PG is Boc.
- LG is a leaving group such as bromo or chloro. 12 is reacted wit H ⁇ R ' h )R presence of a base, such as DIEA, in a solvent such . as ACN.
- LG in Scheme 6 is a leaving group such as chloro.
- the reaction can be earned out by irradiating in a -solvent such, as DMA.
- the reaction can be carried out in the presence of acetic add in a solvent such as DMA and by heating.
- Preparative reverse-phase HPLC was used to isolate die desired, product directly from th crude reaction mixture.
- a Waters Fracti miynx preparative reverse-phase HPLC equipped with a Waters SunFire Prep C IS, OCD 5 iiM, 30 X 70 mm column and running a 5-100 % gradient with a binary solvent system of 25 m . ammonium acetate in watemveetorikrile; was used- to carry out the purification.
- a CB microwave reaction vessel was charged with N ⁇ ( ⁇ N-Q- cidoroquinoxalin-2- l)siiSfa.moyl)phenyl)-2 ⁇ (30 mg, 0.071 mmoi), prepared -using procedures similar to those described in Example 374, the desired aniline ( 36 mg. 0.14. mraol, 2 eq), and 0.5 mL of dimethylacetamide.
- the vessel was sealed and the Discover mierowave instrument. The solvent was then removed by roiary-evaporatiori. Purification of the filial product was accomplished by preparatory reverse-phase HPLC with the eluents 25 mM aqueous NR+OAe ACN to the desired product.
- Example 374 prepared usin procedure similar to those ia Example 374.
- the desired aniline (0.56? mmol, 4 e3 ⁇ 4),-and 1.0 mL of toluene * '
- the vessel was sealed and the reaction mixture wa heated under microwave .radiation for 60 mm at I SO *C hi a CEM Discover mierowave instrument.
- the solvent was removed on a rotary-evaporator. Purification of the final product was done, by preparatory HPLC with. NM OAC/ACN as eluem to yield the desired produet.
- Fractionlynx preparative reverse-phase HPLC equipped with, a Waters SunFire Prep CI 8, OCD 5 ⁇ , 30 X 70 mm column and running .a 5-1.00 % gradient with a binary solvent system of 25 raM ammonium acetate in waten'acetomtnle; W used to cany out the purification.
- Compounds of Formula ⁇ can be made by the synthetic procedures described below.
- the starting materials and reagents used in preparing these compounds are either available from commercial suppliers- such as Aldrich Chemieai.Go, (Milwaukee, Wis,) or Sachem (Torrance, Calif), or are prepared by methods known to those skilled in the art following procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-1.7 (John.
- the starting materials and the ' intermediates of the reaction may be isolated and purified if desired using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography, and the like. Such materials may be characterised using- conventional means, .including physical constants and spectral, data.
- the reactions described herein take place at atmospheric pressure- nd o ver a temperature range, from about. -78 C to -about S 5() '! C, more specifieally from about ( j C to about 125 " C and more specifically at about room (or ambient) temperature, e.g., about 20 °C. Unless othe ' wise stated (as in. the case of an hydrogeaation),, all reactions are performed under an atmosphere of nitrogen.
- Prodrugs can be pre ared by techniques known to one skilled in the art. These techniques generally modify appropriate functional groups in a given compound. These modified functional groups regenerate original functional groups by routine manipulation or i?? viva. Amides and es ters of the compounds of the present invention may he ' prepared according to conventional methods. A thorough discussion of prodrugs is pro vided in T Higuehi and V. Stella, "Pro-drugs as Novel Delivery Systems, *5 Vol 14 of the A..C.S.
- the compounds of the invention may have asymmetric carbon atoms or quaternized nitrogen atoms in their structure.
- Compounds of formula ⁇ that may be prepared, through the syntheses described herein may exist as single stereoisomers, raeemates, and as mixtures of enantiomers and dsastereotuers.
- the compounds may also exist as geometric isomers. Ail such single stereoisomers, mcemaies and. mixtures thereof, and geometric isomers are intended to be within the scope of this invention.
- Some of the compounds of the invention ma exist as lautome ' rs.
- the molecule may exist in the enol form; where an amide is present, the molecule may exist as the iraidic acid; and where an enamine is present, the molecule may exist as an iraine.
- All such tautoraers are within the scope of the invention, in particular, hnidazoI-3-yl and pyrazol-S-yi each can also exist in their respective tautomeric forms t .i a;ioi-4-yl and pyrazol-3-yL Regardless of which structure or which terminology is used, each automer is included within the scope of the invention,
- the present invention also includes -oxide derivatives and protected derivatives of compounds of formula 11,
- compounds of formula 1 when compounds of formula 1 contain an oxidtzable nitrogen atom, the nitrogen atom can be converted to an N-oxide by methods well known in the ar
- compounds of formula I when compounds of formula I contain groups such as hydroxy, earhoxy, thiol or any group containing . a nitrogen atom(s), these groups can be protected with a suitable "protecting group” or "protective group”.
- a comprehensive list of suitable protective groups can be found in TvW. Greene, Protective Groups in Organic Synth ix,. John Wiley ⁇ 3 ⁇ 4 Sons, Inc. 1991 , the disclosure of which is incorporated herein by reference in its. entirety.
- the protected derivatives of compounds of formula I can be prepared by methods well knewn i.n the art.
- stereoisomers from racemic mi xtures or non-racemie mixtures of stereoisomers are well known, in the art.
- optically active (!3 ⁇ 4 ⁇ )- and (Sj- isomers raay be prepared using ehiral synthons or ehiral reagents, or resolved using conventional techniques.
- ⁇ -isomers may be resolved by methods known to one of ordinary skill in the art, for example by: formation of d iastereo isomeric salts or complexes which raay be separated, for example, by crystallization; via formation of diastereoisomerie derivatives which may be separated, for example, by crystallization, selective reaction of one enantiomer with an enantlomer-specific reagent, for example enzymatic oxidation or reduction, followed by separation of the modified and unmodified enantioniers; or gas-liquid or liquid
- enantiomeric form Alternatively, specific enantiomer may be synthesized by asymmetric Synthesis ' using ' optically active reagents, substrates, catalysts, or solvents, or by con verting one enantiomer to the other by asymmetric transformation.
- the major component enantiomer may be further enriched (with concomitant loss in yield ⁇ by reerystaUization.
- the compounds of the present invention can exist in unsolvated as well as soi.vated forms with pharmaceutically acceptable solvents such -as water, cthanol, and the like, in general, the solvated forms are c nside ed equivalent to the ⁇ unsolvated forms for the purposes of the present invention,
- An intermediate of formula 2 is prepared by reacting -tut intermediate of formula i. with .a; primary amine R ! i ⁇ ki a solvent such as water and with heating, 2 is then treated with iodine moaoehioride in a solvent such as methanol at around 0 "C and allowed to react for approxim tely overnight or less as needed for the reaction to o to completion to form 3, Alter completion the residue is triturated with acetone.
- the intermediate 3 is then reacted in solvent, such as DMA, with ethyl actyiate in the presence of a ba e, such as triethyi amine, and in the presenc of a catalyst, such as Pd(OAc); s . and ( ⁇ )BINA P.
- solvent such as DMA
- ethyl actyiate in the presence of a ba e, such as triethyi amine
- a catalyst such as Pd(OAc); s . and ( ⁇ )BINA P.
- the reaction i heated to approximately 100 "C and allowed to react for approximately overnight or less as needed for the reaction to go to completion to form 4> 4 is then .optionally purified by column chromatography.
- 1 . 00307 ⁇ 5 is prepared b treating 4 with DBU in the presence, of a base such as DiPEA at room ⁇ ' temperature.
- the reaction mixture is .then heated to reflux and reacted for
- 10030$ 6 is prepared by reacting 5 with a .brom mating agent such as Br3 ⁇ 4 in a solvent such as .OCM. at room temperature. The reaction mixture is then stirred for approximately overnight, The resulting product is filtered and then suspended in a solvent such as DCM ' aftd treated with a ase suclias irieth lainine. The mixture is then washed with water and dried over a drying, agent such as NajSCk to yield 6.
- a .brom mating agent such as Br3 ⁇ 4 in a solvent such as .OCM.
- a Suzuki, coupling is then ' .performed usin 6 and a boronie acid (or ester) of formula R (1 B(C)H); in a solvent(s) such as a DMB-3 ⁇ 40 mixture in the presence of a catalyst such as Pdidppp ) and a base such as trie thy lanaine at room temperature.
- the reaction mixture is ..heated to reflux for approximately 4 hours-. After cooling to room, temperature, the reaction mixture is- artitioned with, water and ethyl acetate. After separation, the organic layer is dried over a drying agent such as r1 ⁇ 2S ⁇ 1 ⁇ 4 to yield 7.
- An intermediate of formula is prepared fay reacting an intermediate of formula 8 with neat FOCI 3 and heating. 9 is then treated with a primary amin R ! NH ; > in a solvent such as water or THF and. trieihylamine at 0 U C to form 10. After removal of the solvent under reduced pressure, the intermediate 10 is then reacted with lithium aluminum hydride in a solvent such as THF at 0 "C. After quenching and aqueous workup, .solvent removal provided crystalline. 11 without iltrthor purification.
- An intermediate of t rmisia 14 is prepared by reacting an intermediate of formula 13 with a primary amine 'NHj* in a solvent such as water and with heating. 14 is then treated with iodine monoehloride in a solvent such as methanol at around 0 ;> C and allowed to. react for approximately overnight or less as needed for the reaction to go tp completion to form 15. After completion the residue is triturated with acetone. The intermediate 15 is ' then reacted in a solvent, such as DMA, with ethyl acryiate in the presence of a base, such as triethyi amine, and in the presence of a catalyst, such as PDFOAc) ⁇ . and (+)Bi AP.
- a solvent such as DMA
- An intermediate of formula 20 is prepared by reacting an intermediate of formula 19 with neat PQt3 ⁇ 4 and heating. 20 is then treated with a primary -amine ' R'Nj3 ⁇ 4 in a solvent such as water or THF and tnethyiminne at 0 "C to form 21. After removal of the solvent under reduced pressure, the intermediate 21 is then reacted wit lithium-aluminum hydride hi a solvent such as THF at 0 "C, Alter quenching and aqueous workup, solvent removal provides crystalline 22 without, further purification. Treatment of 22 with, manganese (H) dioxide in a solvent such as methylene chloride or chloroform at room temperature provides aldehyde- 23 -upon filtration and solvent removal.
- H manganese
- a Knovenegal-type 'Con ensation with 23 and an arylaceio trile in the presence of a base such as ⁇ potassium carbonate or sodium hydroxide in a pro tic solvent provides the eyefeed trains 24.
- Acetylation of the imine with acetic anhydride is required prior to hydrolysis, which takes place in the presence of aqueous acid and heating to afford 25.
- 25 can be oxidized to the ' ' corres ondin suIJ ' one with »i-CPBA at room temperature and displaced with ammonium to provide 1.
- stage 2 A two-stage Phase 2 study is conducted to evaluate the safety and efficacy of Compound A in subjects: with endometrial carcinoma.
- stage 2 a tablet ibrmulat n- will be used, A 400-mg tablet was chosen as the phase 2 dose based on the observation that the exposure at this dose level was similar to the MTD of capsules at 600 mg.
- the primar objectives of this .study are to evaluate the co-primary efficacy endpoinis; of ( t ) objective tumor re.spon.se nvte (ORR) (co finn d complete response [CR] or confirmed partial response PR)); and 2) rate of 6-month (183 days) progression-free survival (PFS6), in subjects receiving Compound A Tor ad vanced or recurrent EC aad to evaluate the safety and tokrabllity of Compound A in this population.
- ORR objective tumor re.spon.se nvte
- PFS6 progression-free survival
- PB /PTEN patiiway cosnponents/modolators eg, P1K3CA inutation ampSifieation, PTEN deficiency
- P1K3CA inutation ampSifieation, PTEN deficiency eg, P1K3CA inutation ampSifieation, PTEN deficiency
- the study was initially designed as. a two-stage Phase 2 study to evaluate safety and efficacy of Compound A with co-primary efficacy endpoints of ORE and PFS6.
- Part 1 approximately 80 subjects were to be enrolled to obtain 71 evaktabSe subjects per protocol.
- Stage I enrolled 3? evaiuable subjects. If at least four subjects had achieved an objective response (a confirmed PR or a confirmed CR) or at least seven subjects were- alive and progression free for at least 6 months, then the study would have continued to Stage 2 until 71 evaiuable subjects (including both stages) " have been, enrolled.
- Part 2 As of amendment 3 (Part 2), approximatel 45 additional patients will be enrolled to obtain a total of approximately 75 per protocol evaiuable patients (including those enrolled in Part 1 ⁇ .
- the primary interest of Part 2 is the estimation of ORR and PFS6 for all patients meeting the Amendment.3 .mciusion/ ' exciuskm criteria.
- biomarkers thai may predict increased frequency of response or longer disease stabilization. If molecular profiling data obtained during the course of the stud -suggests a predictive .markers] for response or disease stabilization, up to 15 additional subjects; with this tunior-j ioraarker'"sigtta$ui3 ⁇ 4" will be enrolled.
- Qualifying screening assessments must occur wi thin 21 days before the first administration of stud drug; a subset of screening assessments may also be considered the Study Da I pre-trcatment evaluations if done within 4 days before ini ial dosing.
- Treatment Period Subjects are treated and monitored for safety ⁇ ncluding laboratory assessments), signs of toxicity, progressive disease (PD), and
- Tumor assessment visits for each subject will be after Week 8, Week in, and Week 26 following the first dose of study drug, and every JO -weeks thereafter. During Week 9 and beyond subjects mast return to the study site for tumor -assessment visits that may not coincide with- equired, elude visits,
- Post-Treatment Period Subjects return to the study site between 30- nd
- radiographic PD death, or the initiation of subsequent anticance therapy.
- an additional 15 subjects whose tumors exhibit this- biomarker signature may be enrolled.
- the subject has a histologically continued diagnosis of EC (endometrioid, serous, clear cell adenocarcinoma, adenosquamous carcinoma, or mixed histology, any grade ⁇ that is advanced (ie, persistent, locally advanced) or recurrent and is incurable- by standard therapies, and ha received one platinum-based chemotherap regimen for EC.
- EC endometrioid, serous, clear cell adenocarcinoma, adenosquamous carcinoma, or mixed histology, any grade ⁇ that is advanced (ie, persistent, locally advanced) or recurrent and is incurable- by standard therapies, and ha received one platinum-based chemotherap regimen for EC.
- the subject is at least 18 years old,
- the subject has an Eastern Cooperative: Qneology Grou f ECOG) performance; status of 0 or 1 ,
- the subject has at least one lesion that is measurable on computerized tomography (CT) or magnetic resonance- -imaging (M.RTJ scan determined by investigator per RECIST
- CT computerized tomography
- M.RTJ scan magnetic resonance- -imaging
- a lesion within a previously radiated field is only considered measurable if there has been demonstrated progression in the lesion and documented by:
- the subject has organ and marrow function as follows:
- Serum creatinine ⁇ 1 ,5 x ULN calculated creatinine clearance > 60 aiL niin, or glomerular .filtration rate > 40 ml./min
- ALT Alanine atnwptn sfetase
- AST aspartate aminotransferase
- the subject is capable of understanding the informed consent and complying with the protocol and lias signed the informed consent document before any study-specific screening procedures or evaluations are performed.
- -Sexually active subjects must agree t use a medically accepted barrier method of contraception (i.e., male condom or female condom ⁇ during the, course of the ⁇ study and for 3 months following discontinuation of study treatments.
- a barrier ' method and a second method of contraception must be used.
- Horm al contraceptives are discouraged because of. a possible decrease in effectiveness due to a possible drug-dru interaction,
- Subjects of chiidbeanng potential must have a negative pregnancy test at screening.
- Subjects of chiidbeanng potential are defined as premenopausal subjects capable of becoming pregnant (i.e.. subjects who have had any evidence of menses in the past
- the subject has previously been treated with a PB inhibitor, mTOR inhibitor, or AKT inhibitor.
- the subject has uterine sarcomas (leiomyosarcoma),, mixed uUerian tumors, squamous carcinoma of the uterus, and/or adenosarcomas of the uterus.
- uterine sarcomas leiomyosarcoma
- mixed uUerian tumors squamous carcinoma of the uterus
- adenosarcomas of the uterus adenosarcomas of the uterus.
- Cytotoxic chemotherapy including investigational cytotoxic agents
- biologic agents antibodies, immune modulators, cytokines
- nitrosoureas or mitomycin C within 6 weeks, before the iirst dose of Compound
- a small-molecule kinase inhibitor (including investigational small-molecule ' kinase inhibitors) within 2 -weeks, , or five half-lives of the drug or active metabolites, whichever is longer, before the first dose of Compound A:
- the subject has a known primary brain tumor or brain metastasis.
- the subject has any other diagnosis of malignancy or evidence -of malignancy (except noiwmdanoma skin cancer or in situ carcinoma of the cervix) within 2 years before screenin for this study.
- the subject has a diagnosis of uncontrolled diabetes mellitus (glycosylated hemoglobin AIC > 8%) or has a fasting plasma glucose > 160 nig dL,
- The- subject is currently receiving anticoagulation with therapeutics doses of warfarin (low-dose warfarin ⁇ 1 nig/day is permitted).
- the .subject has prothrombin time (:PT ⁇ interaa tionid normalized ratio f l Il ⁇ or partial thromboplastin time (FIT) test results at screening that are above 1.3 ⁇ the laboratory ULN.
- prothrombin time :PT ⁇ interaa tionid normalized ratio f l Il ⁇ or partial thromboplastin time (FIT) test results at screening that are above 1.3 ⁇ the laboratory ULN.
- the subject has uncontrolled, significant intercurrent illness including, but not limited to:
- the subject has a baseline corrected QT interval 470 ms
- the subject is known to be positive for the human iromwiodefrcieney virus (HIV).
- HAV human iromwiodefrcieney virus
- the subject is pregnant or breastfeeding:.
- the subject has a previously identified allergy or hypersensitivity to components of the study treatment f rmulatioE.
- Compound A will be supplied as 100 mg capsules or 100, I SO, and 200 mg tablets. Compound A will be administered at a dose of 600 mg once daily ⁇ capsule) or 400 mg once daily (tablet).
- Tumor assessments will be performed within 28 days before the first dose o study drag , and after Week 8, Week 16, and Week 26 following the first dose of study drag, and every 10 weeks thereafter until the earlier oi documented radiographic P , death, or the initiation of subsequent anti-cancer therapy. Response and progression will be determined per ECiST Version 1.1. Responses will be; confirmed by repeat assessments that should be performed 28-35 days after the response criteria are met.
- Evaluation of baseline disease will include a physical examination, a screening chest x-ray and/or a chest CT scan, an abdominal-pelvic CT or MR! scan, and a tumor .marker CA125 assessment. All tumor lesions must be assessed by GT or MRI scan and physical examination (if appiieable) at each evaluation during the study.
- IRC Independent Review Committee
- Safety will be assessed by evaluation ' of adverse events (AEs), vital signs, electrocardiogram, laboratory 1 tests, and concomitant medications. Adverse event seriousness, severity grade, and relationship to study treatment will be assessed by the investigator.
- CCAE Criteria for Adverse Events v3,0
- Blood samples will be obtained at predetermined time points for Compound A plasma conce trati n assessments.
- PK. samples will also be . collected, if possible, at the 30-day visit during the Post-Treatment Period and whenever a subject has study drug-related SAE(s) (e.g., skin, rash) and or is withdrawn from the study. [00335. ⁇ Detailed instructions for sample preparation and shipping will be provided, in a separate Pharmacokinetic- Laboratory Manual
- Blood, tiunor tissue, and non-lurnor tissue (collected at. the same time as tu or tissue) will -be obtained from consented subjects for analysis of a variety of established and exploratory phaniiacodynamic markers- on. a defined schedule throughout the study.
- Pharmacodynamic studies may include investigation of the impact of target mutations (PI3K. catalytic -and/or regulator;-' subunits) pre-existing in the subject's tumor on response, fluctuation of plasma levels of pathway-relevant proteins (e.g.. vascular endothelial growth factor A fVEGF-A], glucose, and insulin), drag-induced changes in phosphorylation of signal -transduction proteins and lipids (e.g... pEGFR, pAKT. pPRK, pGS . and P1.P3 as well as assess ment of the contribution of complementin genet ic changes in targe t modulators (e.g commencing PTEK RAS, c- ET, HER2, and L B- ' l) on efficacy
- the co-primary efficacy cudpoints are: 1) ORE, defined as the proportion of subjects for whom the beat response is a confirmed CR or confirmed PR, and 2) PfS defined as- the proportion of subjects who survive and are- progression free at least 83 days after the date of the first dose of study ding, Delermmation of response and progression will be- based on -evaluation per RECiST Version 1.1 ,
- AEs will be tabulated by the Medical Dictionary for Regulatory Activities (MedDRA) system organ class and preferred terms. Laboratory test results will be evaluated with respect to changes from baseline
- letrozole and of t he combination of Compound B with ktrozole Phase 1 and Phase 2.
- CB clinical benefit rate
- PBR/ mTOR inhibitor (Ami .2) in combination, with, ietrozoie based on. molecular pro tiling of tumor tissue (Phase" 1 a d Phase 2).
- Phase L subsequent subjects will be enrolled in Phase 2, As of Amendment 3, the doses for Phase 2 are 400 mg qd of Compound A (Arm 1) .and 50 mg bid . ' of Compound B, both in conibii stioo with letrozole 2.5 rag qd.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2671CHN2014 IN2014CN02671A (he) | 2011-09-14 | 2012-09-14 | |
EP12766542.0A EP2755654A1 (en) | 2011-09-14 | 2012-09-14 | Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer |
BR112014005858A BR112014005858A2 (pt) | 2011-09-14 | 2012-09-14 | inibidores de fosfatidilinositol 3-quinase para tratamento de câncer |
AU2012308414A AU2012308414A1 (en) | 2011-09-14 | 2012-09-14 | Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer |
CA2848724A CA2848724A1 (en) | 2011-09-14 | 2012-09-14 | Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer |
KR1020147009539A KR20140077911A (ko) | 2011-09-14 | 2012-09-14 | 암의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제 |
IL231448A IL231448A0 (he) | 2011-09-14 | 2014-03-11 | מעכבי פוספאתידילאינוסיטול 3 – קינאז לטיפול בסרטן |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161534836P | 2011-09-14 | 2011-09-14 | |
US61/534,836 | 2011-09-14 | ||
US201161543529P | 2011-10-05 | 2011-10-05 | |
US61/543,529 | 2011-10-05 | ||
US201161562670P | 2011-11-22 | 2011-11-22 | |
US61/562,670 | 2011-11-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013040337A1 true WO2013040337A1 (en) | 2013-03-21 |
WO2013040337A9 WO2013040337A9 (en) | 2014-04-03 |
Family
ID=46940622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/055387 WO2013040337A1 (en) | 2011-09-14 | 2012-09-14 | Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2755654A1 (he) |
KR (1) | KR20140077911A (he) |
AU (1) | AU2012308414A1 (he) |
BR (1) | BR112014005858A2 (he) |
CA (1) | CA2848724A1 (he) |
IL (1) | IL231448A0 (he) |
IN (1) | IN2014CN02671A (he) |
TW (1) | TW201325592A (he) |
UY (1) | UY34339A (he) |
WO (1) | WO2013040337A1 (he) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113754565A (zh) * | 2021-11-09 | 2021-12-07 | 南京威凯尔生物医药科技有限公司 | 一种连续流微反应器中制备沙库巴曲中间体的方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US20040009993A1 (en) | 2001-12-11 | 2004-01-15 | Pharmacia Italia S.P.A. | Pyridopyrimidinones derivatives as telomerase inhibitors |
WO2007044813A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα |
WO2007044729A2 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
WO2007044481A1 (en) | 2005-10-07 | 2007-04-19 | Basf Corporation | Clearcoat coating composition |
WO2008127594A2 (en) * | 2007-04-11 | 2008-10-23 | Exelixis, Inc. | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer |
WO2010146391A1 (en) * | 2009-06-15 | 2010-12-23 | Generics [Uk] Limited | Regioselective synthesis of letrozole |
WO2012065057A2 (en) * | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
-
2012
- 2012-09-14 KR KR1020147009539A patent/KR20140077911A/ko not_active Application Discontinuation
- 2012-09-14 WO PCT/US2012/055387 patent/WO2013040337A1/en active Application Filing
- 2012-09-14 IN IN2671CHN2014 patent/IN2014CN02671A/en unknown
- 2012-09-14 BR BR112014005858A patent/BR112014005858A2/pt not_active Application Discontinuation
- 2012-09-14 TW TW101133789A patent/TW201325592A/zh unknown
- 2012-09-14 UY UY0001034339A patent/UY34339A/es not_active Application Discontinuation
- 2012-09-14 AU AU2012308414A patent/AU2012308414A1/en not_active Abandoned
- 2012-09-14 EP EP12766542.0A patent/EP2755654A1/en not_active Withdrawn
- 2012-09-14 CA CA2848724A patent/CA2848724A1/en not_active Abandoned
-
2014
- 2014-03-11 IL IL231448A patent/IL231448A0/he unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US20040009993A1 (en) | 2001-12-11 | 2004-01-15 | Pharmacia Italia S.P.A. | Pyridopyrimidinones derivatives as telomerase inhibitors |
WO2007044813A1 (en) | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα |
WO2007044729A2 (en) * | 2005-10-07 | 2007-04-19 | Exelixis, Inc. | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
WO2007044481A1 (en) | 2005-10-07 | 2007-04-19 | Basf Corporation | Clearcoat coating composition |
WO2008127594A2 (en) * | 2007-04-11 | 2008-10-23 | Exelixis, Inc. | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer |
WO2010146391A1 (en) * | 2009-06-15 | 2010-12-23 | Generics [Uk] Limited | Regioselective synthesis of letrozole |
WO2012065057A2 (en) * | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
Non-Patent Citations (24)
Title |
---|
"Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS |
"Fieser and Fieser's Reagents for Organic Synthesis", vol. 1-17, 1991, JOHN WILEY AND SONS |
"Fisher and Fisher's Reagents for Organic Synthesis", vol. 1-17, 1991, JOHN WILEY AND SONS |
"Larch's Comprehensive Organic Transformations", 1989, VICHY PUBLISHERS INC. |
"Larock's Comprehensive Organic Transformations", 1989, VCH.PUBLISHERS INC. |
"March's Advanced Organic Chemistry", JOHN WILEY AND SONS |
"Organic Reactions", vol. 1-40, 1991, JOHN WILEY AND SONS |
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY |
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING COMPANY, EASTON, PA. |
"Rodd's Chemistry of Carbon Compounds", vol. 1-5, 1989, ELSEVIER SCIENCE PUBLISHERS |
"Rod's Chemistry of Carbon Compounds", vol. 1-5, 1989, ELSEVIER SCIENCE PUBLISHERS |
GOODMAN; GILMAN ET AL.: "The Pharmacological Basis of Therapeutics", 1990, PERGAMON PRESS |
J. KASPAREC ET AL., TETRAHEDRON LETTERS, vol. 44, 2003, pages 4567 - 4570 |
M. BARVIAN ET AL., J. MED. CHEM., vol. 43, 2000, pages 4606 - 4616 |
P. L. TOOGOOD ET AL., J. MED. CHEM., vol. 48, 2005, pages 2388 - 2406 |
S. H. DANDEGAONKER; C. K. MESTA, J. MED. CHEM., vol. 8, 1965, pages 884 |
S. M. BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19, XP002675560, DOI: doi:10.1002/jps.2600660104 |
S. N. VANDERWEI ET AL., J. MED. CHEM., vol. 48, 2005, pages 2371 - 2387 |
S. V. LITVINENKO; V. I. SAVICH; D. D. BOBROVNIK, CHEM. HETEROCYCL. COMPD. (ENGL. TRANSL, vol. 30, 1994, pages 340 |
T. HIGUCHI; V. STELLA: "Pro-drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14 |
T. HIGUCHI; V. STELLA: "Pro-drugs as Novel Delivery Systems", vol. 14, A.C.S. SYMPOSIUM SERIES |
T.W. GREENE: "Protective Grotips in Organic Synthesis", 1991, JOHN WILEY & SONS, INC. |
T.W. GREENE: "Protective Groups ill Organic Synthesis", 1991, JOHN WILEY & SONS, INC. |
W. C. LUMMA; R. D. HARTMAN, J. MED. CHEM., vol. 24, 1981, pages 93 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113754565A (zh) * | 2021-11-09 | 2021-12-07 | 南京威凯尔生物医药科技有限公司 | 一种连续流微反应器中制备沙库巴曲中间体的方法 |
Also Published As
Publication number | Publication date |
---|---|
BR112014005858A2 (pt) | 2017-06-13 |
IL231448A0 (he) | 2014-04-30 |
KR20140077911A (ko) | 2014-06-24 |
TW201325592A (zh) | 2013-07-01 |
IN2014CN02671A (he) | 2015-07-03 |
AU2012308414A1 (en) | 2014-05-01 |
WO2013040337A9 (en) | 2014-04-03 |
UY34339A (es) | 2013-04-30 |
EP2755654A1 (en) | 2014-07-23 |
CA2848724A1 (en) | 2013-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6033678B2 (ja) | 併用療法を用いた治療方法 | |
US9532987B2 (en) | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases | |
IL299563A (he) | שיטות לטיפול בלוקמיה מיאלואידית חריפה המאופיינת על ידי הנוכחות של אלל מוטנטי של idh2 והיעדר של אלל מוטנטי של nras | |
RU2672910C9 (ru) | Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы | |
CN105120868A (zh) | 组合治疗 | |
EP2793892A1 (en) | Combination therapies for treating hematologic malignancies using pyridopyrimidinone inhibitors of pi3k/mtor with bendamustine and/or rituximab | |
JP2014055156A (ja) | Bclタンパクの結合パートナーとの相互作用を阻害するための化合物および方法 | |
US20200171033A1 (en) | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer | |
JP6381523B2 (ja) | Pi−3キナーゼ阻害剤の投与レジメン | |
JP2015518888A (ja) | 腫瘍疾患を治療するための17−アルファ−ヒドロキシラーゼ(c17,20−リアーゼ)インヒビターと特定のpi−3kインヒビターとの組み合わせ | |
NZ579945A (en) | Pyrido [2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer | |
WO2018233620A1 (zh) | SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途 | |
KR101401220B1 (ko) | 방사선 치료 증강제 | |
WO2012149308A1 (en) | Method of treating lymphoma using pyridopyrimidinone inhibitors of pi3k/mtor | |
WO2013040337A1 (en) | Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer | |
JP7223998B2 (ja) | Axl阻害剤を有効成分として含む固形がん治療剤 | |
JP2015515476A (ja) | Pi3k阻害剤及びmek阻害剤を使用する癌の治療方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12766542 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014530825 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 231448 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2848724 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/003031 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012766542 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20147009539 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201490619 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2012308414 Country of ref document: AU Date of ref document: 20120914 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014005858 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014005858 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140313 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112014005858 Country of ref document: BR Kind code of ref document: A2 Free format text: - SOLICITA-SE APRESENTAR DOCUMENTOS DE CESSAO DO DIREITO DE PRIORIDADE REFERENTES AS PRIORIDADES REIVINDICADAS NA PUBLICACAO INTERNACIONAL WO2013/040337, CONTENDO OS SEUS DADOS IDENTIFICADORES (TITULARES, NUMERO DE REGISTRO, DATA E TITULO).- SOLICITA-SE APRESENTAR O COMPLEMENTO DO TEXTO DO PEDIDO, TRADUZIDO E ADAPTADO A NORMA VIGENTE, CONFORME DEPOSITO INTERNACIONAL INICIAL (RELATORIO DESCRITIVO E DESENHOS, SE HOUVER). |
|
ENPW | Started to enter national phase and was withdrawn or failed for other reasons |
Ref document number: 112014005858 Country of ref document: BR Kind code of ref document: A2 Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL POR NAO ATENDER AS DETERMINACOES REFERENTES A ENTRADA DO PEDIDO NA FASE NACIONAL E POR NAO TER CUMPRIDO EXIGENCIA FORMULADA NA RPI NO 2518, DE 09/04/2019 |